Flow cytometry with data analysis of optimized dilution of fluid samples for flow cytometry studies
By optimizing the dilution factor range through screening and potency testing modules, the accuracy of flow cytometry instruments in detecting samples with low to high particle concentrations was resolved. This enabled efficient quantification and accurate counting of small particles, reducing operational errors and data processing requirements.
Patent Information
- Application Number
- CN202080006715.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-01-21
- Filing Date
- 2020-01-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-01-14
AI Technical Summary
Existing flow cytometry instruments lack accuracy and precision when detecting fluid samples with low and high particle concentrations, especially in identifying and counting small particles such as viral particles. Furthermore, traditional dilution methods require numerous sample copies and data processing, introducing operator-related errors.
By employing screening and potency testing modules, the optimal dilution factor range is automatically determined. Through flow cytometry studies on a small number of samples, operator involvement is reduced, and data processing efficiency and accuracy are improved.
By optimizing the determination of the dilution factor range, the number of samples and data processing requirements are reduced, improving the accuracy and efficiency of flow cytometry results, reducing operator error, and making it suitable for the quantification of small particles such as viral particles.
Smart Images

Figure CN113167716B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Patent Application No. 16 / 253,060, filed on January 21, 2019, entitled “FLOW CYTOMETRY WITH DATA ANALYSIS FOR OPTIMIZED DILUTION OF FLUID SAMPLES FOR FLOW CYTOMETRY INVESTIGATION,” the entire contents of which are incorporated herein by reference for all purposes. Technical Field
[0003] The present disclosure relates to flow cytometry, including systems and methods for data analysis of flow cytometry results. Background Art
[0004] Flow cytometry is an analytical technique used in several applications to measure the physical and / or chemical properties of biological or non-biological particles as they flow into a sample fluid through a study area in a study cell (commonly referred to as a flow cell). The flow through the flow cell can be studied in the study area by a variety of techniques, including subjecting the flow to excitation irradiation, including, for example, electrical, acoustic and / or optical signals, and measuring and analyzing the response to detect and evaluate the particles in the sample fluid. Although the sample fluid can be studied by subjecting the sample fluid to a variety of stimuli, exposure of the sample to light is a common stimulation technique. Scattered light or fluorescent emissions leaving the flow cell can be detected and analyzed to provide information about the characteristics of the particles present in the sample fluid. Light stimulation and light detection techniques can be customized to identify specific characteristics indicating the presence of a particular type of particle. For example, one technique is to color the sample fluid with one or more stains (also referred to as dyes) associated with a particular biological component of interest. The stain can have a fluorescent activity that provides a fluorescent emission about a specific wavelength, and its detection provides an indication of the presence of the biological component.
[0005] Devices for performing flow cytometry are often referred to as flow cytometers. Flow cytometers are often designed to optimize the detection of specific types of particles (e.g., specific cells, bacteria, viruses, or virus-like particles). A complex problem with the robustness and durability of flow cytometers over time is that flow cytometers tend to be very sensitive instruments that require very precise control of several factors that affect instrument performance. Errors may be introduced into the analysis of flow cytometry results from instrument-related errors (such as alignment of optical elements for optimal performance), chemical-related errors (e.g., mixing of dyes, efficiency of dye binding to samples, etc.), and operator-related errors. Furthermore, any of these three general error sources may introduce noise or other errors, which may degrade the accuracy and / or precision of the flow cytometry results of a given flow cytometry study.
[0006] With respect to instrument-related errors, flow cytometers may experience degradation in performance regarding detection of particles in sample fluids containing very low and very high particle concentrations. For example, in sample fluids with very low particle concentrations, individual particle signals are difficult to distinguish from background signals. At very high particle concentrations, particles have an increased tendency to aggregate and pass through the study area as aggregates rather than one at a time. Therefore, flow cytometers may have a dynamic range relative to the particle concentration in the sample fluid, where the flow cytometer provides acceptable particle identification and counting accuracy. However, such a dynamic range may be specific to a given instrument and / or a study of a specific sample fluid inventory that identifies a specific type of particle with specific particle attributes. In this regard, even in a flow cytometer with known instrument performance characteristics, the dynamic range of a given study of a specific particle type in a specific fluid medium may not be accurately known before the study is initiated. These problems become even more significant for quantitative flow cytometric studies of very small particles (such as particles of the size range of individual viral particles (virions)), which may be as small as tens of nanometers in size. Distinguishing the fluorescent signal from the particles from the background signal becomes more difficult for smaller particles, and the adaptation of light scatter detection for particle identification and gating purposes becomes less feasible. An example of a flow cytometer designed to detect and count virus-sized particles by using fluorescent staining is the Virus 3100 flow cytometer (Sartorius Stedim Biotech) which operates with very low fluid sample flow rates through the flow cell investigation area and incorporates staining by using either nonspecific fluorescent staining for nonspecific binding to protein or nucleic acid components or fluorescent antibody staining for binding to specific binding sites (epitopes).
[0007] Previously proposed solutions to potential accuracy degradation due to samples outside the dynamic range of the instrument and to solve the various error sources mentioned above have included flow cytometric studies of multiple sample copies of each of multiple different dilutions over a wide dilution range of the sample fluid inventory to be studied. This technology has been particularly suitable for flow cytometric evaluation to quantify particles in the size range of viral particles. It is important to perform multiple sample copies at each dilution to evaluate the consistency within the sample at each dilution level. Sampling at multiple different dilutions is important to expand the particle concentration range to be likely within the dynamic range of the flow cytometric instrument for study. Furthermore, the flow cytometric results of multiple sample copies of a wide dilution factor range from a given sample inventory result in a large number of flow cytometric studies having to be performed. In addition, a large group of data is correspondingly generated in this scheme. Statistical schemes can be applied to the data to provide results related to the sample fluid inventory, such as determining the particle concentration in the sample fluid inventory. Such statistical schemes for large data sets may require increased processing power and / or time. For example, three fluid sample copies with dilution factors of 10, 100, 1000 and 10,000 relative to the sample fluid inventory being studied can be prepared, resulting in the preparation and flow cytometry of 12 fluid samples, and subsequent data analysis and computer storage of the flow cytometry results of all fluid samples to ensure a reasonable evaluation of the single sample fluid inventory. As can be understood, such processing requires a lot of time and cost. In addition, such a process usually requires the presence of a relatively large amount of sample fluid inventory to allow the preparation of multiple sample copies over a wide dilution factor range. In addition, the scheme also introduces the opportunity for increased error because conditions may be variable in many required flow cytometric studies. Then, the precision and / or accuracy of the results may be negatively affected. In addition, such data analysis is mainly carried out in a processing environment separated from the flow cytometric instrument, so that no standardized or consistent application of data processing technology is applied to such results. On the contrary, individual operators of flow cytometers may each uniquely process data, thereby having other opportunities for introducing operator-related errors in processing. Summary of the invention
[0008] In view of the foregoing, the present disclosure generally relates to flow cytometry methods and flow cytometry systems that provide data analysis of flow cytometry results to provide improved precision and / or accuracy of studies of target sample fluid inventories performed by flow cytometers. Specifically, the present disclosure generally relates to flow cytometry methods and flow cytometry systems that can efficiently determine an optimized dilution factor range for flow cytometry studies of target sample fluid inventories. In turn, titering of target sample fluid inventories can be performed by studying optimized target fluid samples within the optimized dilution factor range. The schemes described herein can promote error reduction in flow cytometry studies with respect to instrument-related errors, chemistry-related errors, and operator-related errors. Accordingly, more accurate and precise flow cytometry studies can be promoted, thereby improving the functionality of flow cytometry systems that employ the data analysis schemes described herein.
[0009] In general, the present disclosure includes a flow cytometry system, which includes a screening assay module and a titer assay module. The screening assay module is operable to determine an optimized dilution factor range based on an analysis of flow cytometry results from a plurality of screening target fluid samples, in which the flow cytometer of the flow cytometry system is the most accurate. The screening assay module can provide assistance (e.g., automated assistance) for data processing to determine an optimized dilution factor range, such as by providing operator guidance and / or data confirmation capabilities for processing flow cytometry results to determine the optimized dilution factor range. As used herein, the optimized dilution factor range is one or more sample dilution factors within a dilution factor upper and lower limit. The optimized dilution factor range includes an upper and lower limit, and includes the same situation of the upper and lower limits, i.e., when the optimized sample dilution factor range is identified as a single dilution factor value.
[0010] Furthermore, the titer assay module can determine particle titer results (e.g., particle concentrations in a sample fluid inventory being studied) based on flow cytometry results from a plurality of optimized target fluid samples diluted within an optimized dilution factor range. The titer assay module can also provide assistance (e.g., automated assistance) with respect to processing optimized target fluid samples within an optimized dilution factor range to determine particle titer results for the target sample inventory. Again, the assistance provided by the titer assay module can include operator guidance and / or data validation capabilities.
[0011] As used herein, some processes related to the operation of screening assay modules and / or titer assay modules provide confirmation parameters as acceptable values belonging to given parameters. In addition, in the instance where given parameters are not found to be acceptable values, data notifications can be presented to the user. As can be understood in the following discussion, such notifications can provide warnings to the user, to allow the user to confirm calculations or determinations based on the given parameters of the source providing notifications. In certain embodiments, such notifications can exclude the further operation of the module, until and unless the parameters or conditions generating the notifications are resolved. In this regard, such data notifications can provide some confirmations or checks about parameters or conditions related to the operation of screening assay modules and / or titer assay modules. Any such confirmation or inspection of data described herein is intended to be relevant to the specific operation of screening assay modules and / or titer assay modules, and does not reflect the confirmation or inspection of the accuracy of the underlying flow cytometry results used in the processing of screening assay modules and / or titer assay modules. That is, by providing instrument confirmation of the acceptability of parameters or conditions, even with respect to flow cytometry results selected by a user for use in determining an optimized dilution factor range, the embodiments presented herein are not intended to provide any qualitative assessment of the absolute accuracy of flow cytometry results used in conjunction with a screening assay module and / or a titer assay module.
[0012] The aforementioned scheme of determining the optimized dilution factor range using the flow cytometry study of multiple optimized target fluid samples diluted to within the optimized dilution factor range can provide several specific technical advantages about the operation of the flow cytometry system. It is worth noting that the determination of the optimized dilution factor range as described above promotes more efficient system and result processing in several ways. Initially, a screening assay module can be provided, which can access the flow cytometry results to access multiple screening target fluid samples. The screening target fluid sample can include a dilution series of the screening sample inventory diluted with multiple dilution factors. In at least one embodiment of the present disclosure, a limited number of screening target fluid samples (e.g., a single sample under each dilution factor) can be provided for analysis by the screening assay module. Then, fewer screening target fluid samples (e.g., relative to the previously proposed scheme, which uses multiple sample copies under each of the multiple dilution factors) can be subjected to flow cytometry research in order to determine the optimized dilution factor range, to operate within the dynamic range of a given flow cytometry instrument and to a given target sample inventory to be analyzed by a flow cytometer. A set of multiple fluid sample replicates prepared within the identified optimized dilution range can then be subjected to flow cytometry, and the results analyzed to provide particle titer results for the target sample stock with reasonable confidence, as has been done within the high performance portion of the dynamic range of the particular instrument and sample conditions.
[0013] This can provide several advantages over previous flow cytometry instruments and methods. Initially, because fewer sample replicates can be required at each dilution factor, the total amount of screening sample fluid inventory required to determine the optimal dilution factor range can be reduced. This can have particular advantages in the context of a limited supply of screening sample fluid inventory, which otherwise may preclude analysis of a large number of replicates at each dilution factor. In addition, the opportunity for operator-related error can be reduced because the overall operator involvement in preparing and conducting the screening target fluid sample can be reduced.
[0014] In addition, the time required for the flow cytometry study of the reduced number of screening target fluid samples can be correspondingly reduced. This not only provides efficiency in the time required for analysis, but also allows a more compact analysis, which reduces the possibility of introducing errors in the process of each flow cytometry study in the fluid sample. It is understood that the flow cytometry process may be subject to time-related variables, which introduce errors into the flow cytometry study, so that the amount of error or variability in the process increases over time. Therefore, providing a more instantaneous compact analysis can reduce such time-related errors or variability.
[0015] In addition, the number of screening target fluid samples that determine the required reduction of the optimized dilution factor range can also reduce the required computing resources for providing flow cytometry results. As can be appreciated, a large amount of processing resources and / or memory resources of the computing environment that may require the analysis of data for a large amount of flow cytometry research. By limiting the number of screening target fluid samples used, the corresponding reduction in computing resources can be achieved. In addition, because the module described herein can directly access the flow cytometry results stored in the memory, the efficiency of processing more limited results can be further improved, thereby providing a more efficient computing processing environment for operating a flow cytometer as a whole.
[0016] In addition, even when considering optimizing the target fluid sample, a complete flow cytometry assessment with a confidence level of acceptable accuracy can be performed on a target sample inventory with a reduced total number of target fluid samples. This can include a reduction in consumed data analysis processing and computer storage, which can also provide a reduction in power consumption for corresponding instrument operation and data analysis. For example, in the previous technical example mentioned in the above background technology, three copies of target fluid samples prepared at each dilution factor of 10, 100, 1000 and 10,000 were used to prepare and process a total of 12 target fluid samples for the complete assessment of the target sample fluid inventory. However, in the case of the implementation of the technology disclosed in the present invention, in terms of the accuracy of the results of the target sample inventory, an assessment of comparable confidence can be obtained with significantly fewer target fluid samples. For example, efficiency can be achieved by preparing and processing a screening target fluid sample at each mentioned dilution factor with the operation of the screening assay module to obtain an optimized dilution factor range. Furthermore, a total of four screening target fluid samples can be prepared and subjected to study, and then three optimized target fluid samples at a single dilution factor within the optimized dilution factor range are prepared and processed to obtain particle titer results using the operation of the titer assay module. Therefore, in this example of the present disclosure, a comparable evaluation of the target sample inventory is performed by preparing and processing only seven target fluid samples (four screening target fluid samples plus three optimized target fluid samples) instead of the corresponding 12 target fluid samples of the previous technical example. And therefore, less target sample inventory is consumed, less time is consumed to prepare target fluid samples and subject these target fluid samples to flow cytometry, less flow cytometer throughput capacity is consumed, less computer processing power is used for data analysis, less computer storage is used to store a smaller number of flow cytometric results, and less power is consumed to operate the flow cytometer and data processing. In addition, for the number of target sample inventories that can be evaluated by the flow cytometric instrument, the flow cytometric instrument throughput capacity is increased, and the evaluation of each such target sample inventory consumes less instrument wear.
[0017] The flow cytometry method and flow cytometry system of the present disclosure can be advantageously used for the quantification of any specific type of target particles performed by flow cytometry assessment.Such target particles can be cells, which can, for example, have a size of several to tens of microns, or particles of other biological materials of similar size. However, in some preferred implementations, the quantification of very small target particles (and especially target particles with virus size) by methods and systems is particularly advantageous.Such target particles with virus size can have a particle size of or less than 2 microns, 1 micron, 600 nanometers, 300 nanometers or even smaller maximum particle size in some implementations.Such target particles with virus size can have a particle size of at least 10 nanometers, 20 nanometers, 30 nanometers or even larger minimum particle size in some implementations.The particle size identified above refers to the maximum cross-sectional dimension of the particle.Such target particles with virus size can, for example, be virions (free virus particles that are not part of a larger unit (such as infected cells)), virus-like particles, extracellular bodies or microvesicles.Virons or virus-like particles can have enveloped or non-enveloped types. Such virions or virus-like particles can be viruses of any viral family or have properties of viruses of any viral family. Some exemplary viruses are influenza virus, baculovirus, adenovirus, adeno-associated virus, enterovirus, lentivirus, minute virus of mouse, rotavirus, parvovirus and feline leukemia virus.
[0018] The reference to particle herein generally relates to such particle in non-associated state, which is not a part of substantially larger particle unit.By particle being virus size and being non-associated, this means that the particle is not a part of the larger particle structure greater than virus size, such as non-associated particle is not in host cell or adheres to a part of immunoassay beads or microspheres or agglomerates greater than virus size.It should be understood that the target particle of the fluorescent coloring labeling can be slightly larger than unlabeled target particle for the flow cytometry detection by fluorescence emission response, because the added quality of fluorescent labeling.However, the reference to particle size herein, and particularly the reference to the particle of virus size, can refer to the size of the non-associated target particle before coloring and / or refer to the colored target particle of the added quality of the fluorescent coloring comprising the target particle attached.When fluorescent coloring is provided by the fluorescent dye molecule attached to the particle of virus size (for example, virion, extracellular body, virus-like particle or microvesicle), the size of the added size from the dye molecule attached generally will not perceptibly increase the size of the obtained non-associated colored particle, so that the non-associated colored particle also has virus size, even if slightly larger than uncolored particle. Similar to fluorescent antibody staining, the particles of staining will be larger than unstained particles, but still have the size of viruses. Some typical exemplary fluorescent antibody staining can be on the order of about 7 nanometers in size, and can therefore increase the size relative to unstained particles on the order of about 14 nanometers when the fluorescent antibody staining is directly bound to the target particle. As the particle size of the staining increases, the indirect binding for fluorescent antibody staining may be slightly larger, wherein the first antibody is bound to the target particle, and the second antibody with a fluorophore is bound to the first antibody to provide a fluorescent label on the particle.
[0019] In the following description, including the claims, and in the accompanying drawings, aspects and exemplary implementation embodiments of the methods and systems of the present disclosure are set forth. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1A-1B are perspective and side views of one embodiment of a flow cytometer instrument.
[0021] Figures 2A-2D can be included in Figure 1A-1B A perspective view, a top view, and an end view of one embodiment of internal components of a flow cytometer within a flow cytometer instrument.
[0022] Figure 3 is a schematic diagram of an embodiment of a flow cytometry system comprising a screening assay module and a titer assay module.
[0023] Figure 4-8 is a graph plotting flow cytometry results that are presented for analysis to determine the dynamic range of the instrument for processing a target sample fluid inventory and to determine its optimal dilution factor range.
[0024] Fig. 9 is an example of a screen of a graphical user interface providing a results listing corresponding to flow cytometry results.
[0025] Fig.10 is an example of a screen of a graphical user interface used in the selection of flow cytometry results for data processing.
[0026] Fig.11 Detailed Description of the Invention An example of a screen of a graphical user interface for controlling and interacting with a screening assay module for determining an optimal dilution factor range.
[0027] Fig.12 yes Fig.11 An embodiment of a screen in which a determination of an optimal dilution factor range has been determined and displayed to a user.
[0028] Fig.13 yes Fig.11 An embodiment of a screen in which a determination of an optimal dilution factor range has been determined and displayed to a user and in which a data notification indication is presented.
[0029] Fig.14 Is to show about Fig.13 An embodiment of a screen showing a detailed list of data notifications in which a data notification indication is presented.
[0030] Fig.15 Detailed Description of the Invention An embodiment of a screen of a graphical user interface for controlling and interacting with a potency assay module for determining an optimized particle titer result for a target fluid sample within an optimized dilution factor range.
[0031] Fig.16 yes Fig.15 An example of a screen in which a particle titer result has been determined and a data notification indication is presented.
[0032] Fig.17 is a curve that plots sample eligibility restrictions relative to flow cytometry results. DETAILED DESCRIPTION
[0033] Although the invention is susceptible to various modifications and alternative forms, specific embodiments of the invention are shown by way of example in the drawings and are described in detail herein. However, it should be understood that it is not intended to limit the invention to the specific forms disclosed, but on the contrary, the invention will cover all modifications, equivalent forms and alternative forms falling within the scope of the invention defined by the claims.
[0034] As used herein, a sample inventory or sample fluid inventory refers to a batch of material having a fluid medium and which is the subject of a flow cytometric study for the presence of particles having specific particle attributes or properties, and such particles that are the subject of the study are referred to herein as target particles. Such a sample inventory may be, for example, a sample batch collected from a bioprocess or the result of further processing from such a collected sample batch, such as a purification process. A plurality of fluid samples for flow cytometry processing are prepared using portions of such a sample inventory, such as preparing fluid samples at different dilutions or preparing multiple copies of fluid samples at the same dilution level. A target sample inventory refers to a sample inventory that is the final subject of quantification of target particles and is used to prepare an optimized target group having a plurality of optimized target fluid samples, each of which is diluted to within an optimized sample dilution factor range. A screening sample inventory refers to a sample inventory that is used to prepare a screening target group having a plurality of screening target fluid samples for determining an optimized dilution factor range by executing a screening assay module. In a preferred implementation, the target sample inventory and the screening target sample inventory are the same sample inventory that are both used to prepare screening target fluid samples for processing to determine an optimized dilution factor range by executing a screening assay module, and to prepare optimized target fluid samples for processing to determine a particle titer result by executing a titer assay module. However, in some alternative implementations, the screening sample inventory can be a different sample inventory than the target sample inventory, although in such implementations, the screening sample inventory and the target sample inventory should preferably be obtained under conditions where the screening sample inventory and the target sample inventory are expected to have generally equivalent compositional properties (including with respect to target particle composition) so that determination of an optimized dilution factor range using the screening sample inventory will reasonably translate to flow cytometric evaluation of an optimized fluid sample prepared using the target sample inventory. For example, the target sample inventory can be a collected sample batch or prepared from material collected from a biomanufacturing process on a single day, and the screening sample inventory can be an equivalently collected sample batch or prepared from material collected from the same biomanufacturing process under similar conditions at different times (such as at different times on the same day or on different days under equivalent operating conditions). As mentioned, however, in preferred implementations, the target sample inventory and the screening target sample inventory are the same sample inventory (eg, a single collected batch of samples).
[0035] The specific particle attribute of target particle can comprise one or more than one property of any target particle, for example, relates to size, component, morphology or conformation (conformation) property.In some preferred implementations, the specific attribute of target particle can comprise one or more specific biological characteristics of concern, which are easy to identify by using one or more fluorescent stainings.Such biological characteristics can comprise protein components and / or nucleic acid components (for example, the presence of genomic material), which are generally easy to be nonspecifically colored by nonspecific fluorescent stainings.Such biological characteristics can comprise the presence of specific epitopes, which can be identified by specific antibody binding activity, such as antibody staining specifically bound to the particle feature of concern, to be identified by using fluorescent antibody staining.Implementation can use a single fluorescent staining that identifies the presence or absence of a single particle feature or can use multiple fluorescent stainings that identify multiple particle features.Using multiple fluorescent stainings can comprise flow cytometry assessment, to identify target particles with multiple particle attributes by identifying consistent fluorescent responses from two or more than two such fluorescent stainings, or to identify the presence of a factor and the absence of another factor by identifying a fluorescent response of a fluorescent staining that is inconsistent with the fluorescent response of a second fluorescent staining. An example of such application comprises the overall presence of non-specific fluorescence staining for identifying protein components, and the overall presence of another non-specific fluorescence staining for identifying nucleic acid components. The identification of the consistent occurrence of the fluorescence response of two non-specific stainings during flow cytometry can indicate the presence of the target particle comprising both protein components and nucleic acid components, such as can be the situation of, for example, an intact virion, which comprises envelope or capsid protein and genomic material. Another example of such application comprises epitope-specific fluorescent antibody staining and non-specific fluorescence staining for nucleic acid components. Fluorescent antibody staining can specifically bind to epitopes on the viral envelope, viral capsid, exosomes, or microvesicles, and recognition of consistent occurrences of such fluorescent antibody staining and fluorescent responses of nonspecific nucleic acid staining during flow cytometry can indicate the presence of target particles that contain epitopes and genomic material, such as in the presence of intact viral particles of the virus type represented by such epitopes (e.g., a specific virus), while recognition of inconsistent fluorescent responses of one fluorescent staining with another fluorescent staining can clearly indicate the presence of particles having one particle characteristic but not having another particle characteristic corresponding to a different fluorescent staining (e.g., virus-like particles having viral epitopes but not a genome).Additional information about fluorescent staining and staining detection using flow cytometry that can be used with the present disclosure is disclosed in U.S. Patent Nos. US 10,161,850 B2, US 10,031,061 B2, US 9,546,936 B2, US 9,903,803 B2 and in U.S. Provisional Patent Application No. 62 / 713,377, the entire contents of each of which are incorporated herein by reference for all purposes. In contrast to target fluid samples (e.g., screening target fluid samples and optimizing target fluid samples) that are the subject of research on target particles, blank control fluid samples (e.g., screening blank control fluid samples and optimizing blank control fluid samples) are fluid samples that are intentionally prepared to be free of target particles. Blank control fluid samples can be provided for flow cytometry evaluation to generate blank control flow cytometry results with background particle counts, which can be used to correct flow cytometry results from flow cytometry evaluation of target fluid samples (e.g., screening target fluid samples or optimizing target fluid samples) that are being studied for the presence of target particles. By being free of target particles, this means that the fluid sample is substantially free of target particles for all practical purposes of flow cytometry quantification, rather than such blank target samples which may contain even a single such target particle, although this would be generally preferred. Preferably, the blank control fluid sample corresponds closely to the corresponding target fluid sample in composition, except that it does not contain any or any significant amount of target particles. In some more preferred implementations, the blank control fluid sample is prepared using the blank sample fluid matrix of the corresponding sample inventory, for which the blank control fluid sample will be used for correction purposes. Fluid matrix means that the basic components of the fluid medium of the sample inventory form the liquid medium of the target fluid sample prepared by the sample inventory together with the added reagent liquid. Such added reagent liquid may include, for example, a sample dilution buffer for preparing a fluid sample diluted relative to the sample inventory, and a liquid that can be added in conjunction with the fluorescent coloring of the target fluid sample. Each such blank control fluid sample should preferably be prepared using the same one or more fluorescent colors used in the corresponding target fluid sample and at the same concentration. Preferably, at least one (and more preferably only one) such blank control screening fluid sample prepared using the corresponding fluid matrix is prepared for each screening target fluid sample of the screening target group. Preferably, at least one (and more preferably only one) optimization blank control fluid sample prepared using a corresponding fluid matrix is prepared for each optimization target fluid sample of the optimization target group.
[0036] When the fluid matrix of sample inventory is not available for preparing corresponding blank control fluid sample, then approximate liquid formula can be used to prepare corresponding blank control fluid sample.For example, blank control fluid sample can be prepared using one or more (for example, the mixture of the buffer solution of dilution of sample inventory and the liquid added in conjunction with sample coloring) in the reagent liquid for preparing target fluid sample.In this case, single blank control fluid sample component of one or more fluorescent colorings prepared using such reagent liquid formula and containing the same concentration as screening target fluid sample can be used as corresponding screening blank control fluid sample or corresponding optimization blank control fluid sample of screening control group or optimization control group, as the case may be.
[0037] Flow cytometers can be used to perform flow cytometric studies of fluid samples. Fluid samples can contain target particles with specific particle properties. Flow cytometric studies of fluid samples can provide flow cytometric results of fluid samples. Flow cytometric results can include quantitative indications of particles of fluid samples. In one example, the quantitative indication can be expressed as particle concentration, or particles per unit volume, (e.g., particles / mL). In another example, the quantitative indication can be expressed as a particle count (number of particles) in a standard volume of fluid sample, from which the particle concentration can be determined. The fluid sample can be exposed to a coloring or dye, which provides a response irradiation when exposed to the research excitation irradiation, which can be measured by the irradiation detection system of the flow cytometer. As described above, and especially in applications where the particles to be measured have a viral size, the flow cytometer instrument is very sensitive, and the accurate determination of the flow cytometer results with reasonable accuracy may be difficult. Specifically, the flow cytometric results can be subject to errors for several sources as described above.
[0038] Accordingly, when designing a flow cytometry study to achieve appropriately and demonstrably accurate results, conventional practice is to process many copies of a fluid sample to calculate a measure of the accuracy and / or precision of the resulting flow cytometry results. This may be desirable to demonstrate that the flow cytometry results are sufficiently accurate and / or precise for a given analysis to be performed, and that the results are statistically robust. For example, at least three copies of a target sample fluid may each be subjected to flow cytometry to obtain results for each of the three copies. In turn, the flow cytometry results of the copies may be processed using data analysis techniques to provide a measure of the accuracy and / or precision of the results.
[0039] In addition, in many research designs, control can also be subjected to flow cytometry research to provide the enhanced accuracy of research. A blank control fluid sample can be provided, which replicates or simulates the component of the fluid medium of the target particle of the target fluid sample to a reasonable extent. For simplicity, the blank control fluid sample can also be referred to as control fluid sample or blank fluid sample in this article. Because the flow cytometry research of fluid sample may be susceptible to the influence of misdetection events, the flow cytometry research of the corresponding control fluid sample can allow misdetection events to be taken into account and corrected in the flow cytometry results of the gained of the target fluid sample. Specifically, the flow cytometry results of the control fluid sample can be subtracted from the flow cytometry results of the target fluid sample.
[0040] In one embodiment of the research design, blank control fluid samples can be prepared using the fluid matrix of the corresponding sample inventory, but the target particles of the target fluid sample are not contained. In this regard, the blank control fluid sample can be the component identical with the target fluid sample matrix plus the reagent (such as dilution buffer solution and coloring liquid, and the dye or coloring used in the target fluid sample) added. In an alternative, the sample buffer solution comprising the mixture of such reagent liquid can be used, and it can also be provided with the dye or coloring of the target fluid sample, also without target particles. In any respect, any particle detected in the blank control fluid sample is assumed to represent the error associated with misdetection, so that the actual quantitative correction measurement of the particle in the target fluid sample is provided for the control fluid sample minus the flow cytometry result. However, for the situation of the target fluid sample, multiple copies of the control fluid sample are preferably subjected to flow cytometry research to provide the accurate result of the control fluid sample.
[0041] Accordingly, it can be appreciated that subjecting each of the many target fluid samples and control fluid samples to flow cytometry research may provide several challenges. Initially, in order to provide the desired number of copies of both the target fluid sample and the control fluid sample, a sufficient supply of sample inventory and control inventory with corresponding fluid matrix is required. In certain contexts where there is a limited inventory supply or when the blank fluid matrix of the sample inventory is unavailable, the resulting design of the flow cytometry study may be limited in view of the limited inventory fluid supply. In addition, the time and expense required to process each of the target and control sample fluids may be too high. In addition, since the flow cytometry instrument may be sensitive to several variables, some of which may be operation-related or time-related, a larger number of studies over a longer period of time introduce sensitivity to increased errors in the study of each fluid sample. That is, in the context of many fluid sample studies, the conditions associated with the first fluid sample study may be different from the conditions of the last fluid sample, so that the change in the conditions represents an increased error in the result to be processed as a whole. Therefore, the efficiency of the study not only provides a simple benefit of reduced time and expense, but also achieves inherently more accurate results by reducing the possibility of errors introduced into the process of determining the flow cytometry results of a given invitation design.
[0042] Figure 1A-1B An embodiment of a flow cytometer 100 is shown, which includes flow cytometric components contained within a protective housing 102, which can be used to perform flow cytometric studies on fluid samples to generate flow cytometric results. The fluid sample can be introduced into the flow cytometer 100 through a sample inlet 104 to perform flow cytometric studies. The flow cytometer 100 includes a support pad 106, and the weight of the housing 102 and the components within the housing 102 is supported on the support pad 106. Advantageously, the support pad 106 can be a material that provides significant vibration isolation for the housing 102 and the components within the housing 102 from ambient vibrations, which can be transmitted by a shelf, table or other surface on which the flow cytometer 100 is placed during use. The support pad 106 can thus provide a vibration isolation structure that provides a vibration propagation barrier for the housing 102 and the components within the housing 102. For example, the support pad 106 can be a polymer composition that provides a vibration decomposition effect. Exemplary polymer compositions include thermoplastic and thermosetting polymer compositions.
[0043] Figure 2A-2BAn exemplary flow cytometer internal assembly 180 is shown, which can be disposed within the housing 102 of the flow cytometer 100. The internal assembly 180 includes a flow optical system assembly, including a support platform 200 and a number of flow cytometry optical components supported by the support platform 200, the optical components having a fixed relative positioning configured to perform flow cytometric studies of sample fluids. The flow cytometry optical system assembly is supported by a support structure, the support structure including three solid support members 202 and vibration isolation mounts (at Figure 2A-2B ), and during flow cytometry research operations, the entire weight of the support platform 200 and the components supported by the support platform 200 is supported thereby.
[0044] The flow cytometry optical assembly supported by the support platform 200 includes a light source in the form of a laser unit 206, a flow cell unit 208, and a light detection system including a dichroic mirror unit 210 and two light detector units 212, which may include photomultiplier tubes, for example. During operation of a flow cytometric study of a sample fluid flowing through an investigation flow path of a flow cell of the flow cell unit 208, light from the laser unit 206 travels along a first optical path 250 to the flow cell. The first optical path 250 includes a mirror unit 214 including an orientable mirror that reflects light from the laser unit 206 to direct the light through a focusing lens 216, thereby focusing the light near the investigation flow path within the flow cell of the flow cell unit 208. The orientation of the mirrors of the mirror unit 214 may be controlled by operating one or both of a pair of motors 270, 272 coupled to the mirrors. Light from the investigation flow path of the flow cell is directed from the flow cell to the dichroic mirror unit 210 along a second optical path 260 to be detected by the light detector 212. The second optical path 260 includes a focusing lens unit 218 and a spatial lens unit 220 between the flow cell unit 208 and the dichroic mirror unit 210. The dichroic mirror within the dichroic mirror unit 210 divides the light into light that passes through the dichroic mirror and is directed toward the light detector 212a, and light that is reflected by the dichroic mirror and is directed toward the light detector 212b. A bandpass filter 222 may be disposed in the optical path to the light detector 212 to pass narrow light containing a wavelength or a band of wavelengths targeted for detection by the respective light detectors 212a, 212b.
[0045] During operation of the flow cytometer 100 to perform flow cytometric studies of a fluid sample, the fluid sample to be studied may be introduced into the flow cytometer through the sample inlet 104. The sample fluid is directed to the inlet of the flow cell unit 208 (at Figure 2A-2B226). The sample fluid flows through an investigation fluid path, which is also referred to herein as a flow cytometer investigation zone in the flow cell unit 208, and leaves the flow cell unit 208 through a sample outlet 226. The sample fluid introduced into the flow cell unit 208 through the sample fluid inlet 104 flows through a transparent section of the flow cell unit 208, where it is subjected to incident investigation irradiation (e.g., light from the laser unit 206) and leaves through the sample outlet 226. The investigation flow path passes through the transparent section. The transparent section can be made of, for example, a quartz crystal material. Between the sample inlet 104 of the flow cytometer 100 and the inlet to the flow cell unit 208, the fluid sample passes through a fluid path (not shown), which includes a flow meter 232, at which the flow rate of the fluid sample can be measured to control the fluid sample flow rate to the flow cell unit 208 for data collection purposes as part of a feedback control mechanism. In the flow cell unit 208, a sheath fluid is introduced around the fluid sample flow before the fluid sample flows through the transparent section for investigation. The sheath fluid is introduced through the sheath fluid inlet ( Figure 2A-2B Before the sheath fluid is introduced into the flow cell unit 208, the sheath fluid passes through the fluid path ( Figure 2A-2B 200), the fluid path includes a flow sensor 234 to monitor the sheath fluid flow rate to the flow cell unit 208 and for feedback control to control the flow rate of the sheath fluid to the flow cell unit 208. The flow sensors 232 and 234 are conveniently supported on the support platform 200.
[0046] Additional References Figure 3 , depicts a schematic representation of an embodiment of a flow cytometry system 300. The flow cytometry system 300 may include a flow cytometer 100, such as the flow cytometer described above. The flow cytometer 100 may be operable to generate flow cytometric results for a fluid sample subjected to a flow cytometric study using the flow cytometer 100. The flow cytometric results generated by the flow cytometer 100 may include a quantitative indication of the particles of a given fluid sample (e.g., a particle count or a particle concentration). The flow cytometric results may also include other information about the flow cytometric study, including but not limited to a sample name for identification purposes, a dilution factor of the sample, a date / time stamp corresponding to the date / time of the flow cytometric study, individual results for corresponding study channels of a multi-channel study (e.g., including combination dyes that employ different target particle properties to be studied on corresponding channels), and irradiation detection data, such as detector baseline, peak, and width.
[0047] The flow cytometer 100 can be in operable communication with a flow cytometry result database 310. The flow cytometer 100 can provide the flow cytometry results of each fluid sample subjected to the flow cytometric study performed by the flow cytometer 100 to the flow cytometric result database 310, and the flow cytometric result can be stored in a computer memory in the flow cytometric result database 310. The flow cytometric result database 310 can include any appropriate database structure to store database entries corresponding to the flow cytometric results of different corresponding fluid samples subjected to the flow cytometric study. A specific exemplary implementation can be an SQL database to store the flow cytometric results. The flow cytometric result database 310 can be local to the flow cytometric system 300 (e.g., on a device common to one or more other elements of the flow cytometric system 300) or can be provided remotely. In the case where the flow cytometric result database 310 is provided remotely, access to the flow cytometric result database 310 can be provided via network communication, such as a local area network or a wide area network, such as the Internet.
[0048] The flow cytometry system 300 also includes a computer memory 320. The computer memory 320 may store therein a screening assay module 360 and a titer assay module 370. The screening assay module 360 and the titer assay module 370 may include machine-readable instructions stored in the computer memory 320. In this regard, the screening assay module 360 and the titer assay module 370 may be accessed by one or more processors 330 that are operatively communicated with the computer memory 320. The processor 330 may access and execute the screening assay module 360 and the titer assay module 370 to provide the functionality of the module, as described in more detail below. In other embodiments, the screening assay module 360 and / or the titer assay module 370 may include any appropriate hardware, software, firmware, or a combination thereof to provide the functionality associated with the screening assay module 360 and / or the titer assay module 370 described below. Additionally, a plurality of processors 330 may be provided that may individually or collectively access and execute the screening assay module 360 and the titer assay module 370 to provide the functionality of the flow cytometry system 300 described more fully below. In other embodiments, the screening assay module 360 and / or the titer assay module 370 may include any suitable processor and / or memory combination, an application specific integrated circuit, a field programmable gate array, or other computer hardware or software that may be executed to implement the functionality described in more detail below.
[0049] The flow cytometry system 300 may also include an input device 340 and a display 350, each of which is in operable communication with the processor 330. In this regard, the processor 330 may receive user input from the input device 340 for interacting with or controlling the flow cytometry system 300. Additionally, the processor 330 may configure the display 350 to present information regarding the operation of the flow cytometry system 300 to a user in a user-perceivable manner. The display 350 and the input device 340 may collectively provide a graphical user interface 380 through which interaction between a user and the flow cytometry system 300 may be facilitated. For example, the graphical user interface 380 may facilitate control of the operation of one or more of the flow cytometer 100, the screening assay module 360, the titer assay module 370, and / or the flow cytometry results database 310. Several graphical user interface screens are discussed below that may correspond to the execution of the screening assay module 360 and / or the potency assay module 370, which may be provided for interactivity with a user using the graphical user interface 380 through representation of the screens on the display 350 and receiving corresponding input regarding the screens from the user input device 340.
[0050] In general, the flow cytometry system 300 can be implemented so that the screening assay module 360 is operable to access the flow cytometry results in the flow cytometer results database 310 for use in determining the optimal dilution factor range. In conjunction therewith, the screening sample fluid inventory 390 can be used to prepare a plurality of screening target fluid samples 392, which can each be subjected to a flow cytometric study performed by the flow cytometer 100. The flow cytometric results for each of the screening target fluid samples 392 can be stored in the flow cytometric results database 310. In addition, one or more screening blank control fluid samples 398 can be prepared and subjected to a flow cytometric study performed by the flow cytometer 100, so that the flow cytometric results for the one or more screening blank control fluid samples 398 can be stored in the flow cytometric results database 100. Accordingly, the screening assay module 360 can access the flow cytometry results database 310 to retrieve flow cytometry results for the screening target fluid sample 392 and / or the screening blank control fluid sample 398 for use in determining an optimal dilution factor range, as will be discussed in more detail below.
[0051] Furthermore, a plurality of optimized target fluid samples 396 may be prepared from the target sample fluid inventory 394. The plurality of optimized target fluid samples 396 may each be within an optimized dilution factor range (e.g., as determined by the screening assay module 360), and may optionally all be of the same dilution factor within the optimized dilution factor range. In an embodiment, the screening sample fluid inventory 390 and the target sample fluid inventory 394 may be the same fluid inventory. In an alternative embodiment, the screening sample fluid inventory 390 may be an equivalent approximation of the target sample fluid inventory 394 as described above. For example, the screening sample fluid inventory 390 and the target sample fluid inventory 394 may have the same target particles and may have sufficiently similar properties (e.g., including fluid medium composition and target particle concentration) such that the flow cytometric results of the screening target fluid sample 392 accurately model the performance of the flow cytometer 100 relative to the optimized target fluid sample 396. One contemplated example may be with respect to a predictable processing environment in which the target sample fluid inventory 394 is to be analyzed. In such a predictable processing environment, the target sample fluid inventory 394 can have relatively consistent properties such that an optimized dilution factor range determined by analyzing flow cytometry results of screening target fluid samples 392 can be applicable to several target sample fluid inventories 394. For example, a given instance of a plurality of target sample fluid inventories 394 can be used as a screening sample fluid inventory 390 such that the analysis to determine the optimized dilution factor range can be applied to the remaining plurality of target sample fluid inventories 394. Thus, results obtained using results from a given screening sample fluid inventory 390 can be applied to other target sample fluid inventories 394 prepared for a given time or number of fluid inventory instances in a predictable processing environment.
[0052] In any aspect, an optimized target set of optimized target fluid samples 396 within the optimized dilution factor range can be subjected to flow cytometry studies performed by the flow cytometer 100, and the corresponding flow cytometry results of the optimized target fluid samples 396 can be analyzed by the titer assay module 370 to provide particle titer results for the target sample inventory 394. Additionally, an optimized blank control fluid sample 399 can also be prepared and subjected to flow cytometry studies performed by the flow cytometer 100. In turn, the flow cytometry results of the optimized blank control fluid sample 399 can be stored by the flow cytometry results database 310 and can be used as a control for analysis by the titer assay module 370 in determining the particle titer results.
[0053] Determining the optimal dilution factor range and subsequent flow cytometric studies of the optimized target fluid sample 396 within the optimal dilution factor range can provide improved accuracy and precision of the particle titer results generated by the titer assay module 370. For example, a reduced number of screened target fluid samples and / or screened control fluid samples may be required for operation of the flow cytometric system 300. In turn, a reduction in error may be achieved by reducing the number of studies required. Additionally, by determining the optimal dilution factor range, accuracy of the studies of the resulting optimized target fluid sample 396 may be achieved because the optimal dilution factor range may be specific to a given flow cytometer 100 for studying a particular target particle of the target sample fluid inventory 394.
[0054] With respect to an optimized target dilution factor range, improved accuracy within that range can be achieved by conducting flow cytometric studies of an optimized target fluid sample 396 within the dilution range over which the flow cytometer 100 exhibits improved accuracy. A flow cytometer can exhibit an operating range relative to the concentration of particles in a fluid sample. That is, a flow cytometer may not be able to produce sufficiently accurate results for fluid samples having extremely high concentrations of particles and extremely low concentrations of particles, as described above. In this regard, the range of particle concentrations in a fluid sample over which a flow cytometer can produce sufficiently accurate results may be limited. The range of an instrument can have an absolute range over which the flow cytometer 100 is operable, as well as a dynamic range that depends on the instrument and the specific fluid sample being studied. The dynamic range of an instrument can refer to the range of particle concentrations over which a fluid sample at various dilution factors exhibits linear flow cytometric results (in a logarithmic analysis system as discussed below). With respect to analysis of determining the dynamic range of a flow cytometer Figure 4-8 This analysis may be referred to as a screening analysis, and such analysis may be performed by a screening assay module 360, as described in more detail below.
[0055] Figure 4 A log-log plot 400 of flow cytometry results for a screening target set 406 comprising screening target fluid samples 406a, 406b, 406c, and 406d. The plot 400 also comprises flow cytometry results for a screening control set 408 comprising screening blank control fluid samples 408a, 408b, 408c, and 408d. The vertical axis of the plot 400 represents a logarithmic scale of particle concentration values 402, and the horizontal axis represents a logarithmic scale of sample dilution factor values 404. In turn, the target screening set 406 and the screening control set 408 are plotted relative to the particle concentration 402 and the dilution factor 404.
[0056] Also shown in the curve 400 is an instrument qualification limit (IQL) 410. The IQL 410 represents the minimum particle concentration of the fluid sample for which the flow cytometer 100 provides sufficiently accurate results, and can define a lower limit on particle concentration with respect to the absolute range of the flow cytometer instrument. Accordingly, any flow cytometer results for which the screening target fluid sample 406 is below the IQL 410 can be discarded from any analysis because the screening target fluid sample 406 is at a concentration below the IQL 410 for a given instrument. For example, in Figure 4 , the flow cytometry results for the screening target fluid sample 406d are below IQL 410 and may therefore be discarded from any analysis of the flow cytometry data.
[0057] As can be understood from curve 400, the particle concentration 402 of each corresponding fluid sample depicted in curve 400 decreases with increasing dilution factor 404, as theoretically expected. That is, in theory, the relationship between particle concentration 402 and dilution factor 404 should be linear on a log-log curve, reflecting a commensurate decrease in particle concentration in the fluid sample as the sample is gradually diluted. However, due to instrument limitations and errors, actual flow cytometry results may not adhere to the linear relationship of the idealized theoretical case. Specifically, fluid samples at high particle concentrations may have underreported particle counts, and fluid samples at low particle concentrations may have overreported particle counts, resulting in "flattening" of the data at high and low particle concentrations. Furthermore, the quality of the linearity of flow cytometry results obtained at multiple dilution factors can be evaluated, as will be described in more detail below. It should be understood that, Figure 4 The log-log relationship can be equivalently plotted as a transformed linear curve of the logarithmic value of the particle concentration and the logarithmic value of the dilution factor.
[0058] Further references Figure 5, a curve 500 in the form of such a linear transformation is provided, whose vertical axis represents a linear scale of the logarithmic value of the particle concentration 502, and the horizontal axis represents a linear scale of the logarithmic value of the dilution factor 504. Curve 500 shows a plurality of corrected quantitative indications 506 for a plurality of screening target fluid samples. As described above, the corrected quantitative indications 506 can correspond to the flow cytometric results of the screening target fluid samples as corrected by the flow cytometric results of the corresponding screening blank control fluid samples. After the corrected quantitative indications 506 have been plotted, a fit of the corrected quantitative indications 506 can be calculated. The fit can provide a quantitative measurement or characterization of the corrected quantitative indications 506. For example, the fit can provide a dilution quality parameter, which can be analyzed to determine whether the corrected quantitative indications 506 represent sufficiently linear results, thereby indicating that the flow cytometric results of the screening target fluid samples have a concentration that falls within the dynamic range of the flow cytometer 100 with improved accuracy.
[0059] Further references Figure 6 , a fit may be calculated for the corrected quantified indication 506. For example, a linear regression may be calculated based on the corrected quantified indication 506, such that a resulting trend line 508 may be generated. The resulting trend line 508 may provide a quantitative characterization of one or more dilution quality parameters for use in evaluating whether the corrected quantified indication 506 to which the fit is calculated is within the dynamic range of the flow cytometer 100. That is, the trend line 508 may provide a mechanism for evaluating the corrected quantified indications 506a, 506b, and 506c to determine whether the corrected quantified indications 506 on the curve 500 exhibit a certain level of expected behavior corresponding to the characteristics of the flow cytometer 100 corresponding to results within the dynamic range of the flow cytometer 100 with improved accuracy. One quantitative characterization of the fit of the dilution quality parameters may be the slope of the trend line 508 with respect to such a linear transformation curve, as shown for the curve 500. In this case, ideal performance (i.e., all corrected quantified indications 506 fall within the linear dynamic range of the flow cytometer 100) may be represented by a slope value of -1. Such a linear equation may be of the form y=mx+b, where m is the slope and b is the vertical intercept at the logarithm of zero of the dilution factor. In this regard, a linear equation 510 representing trend line 508 may be provided on curve 500, as Figure 6 The linear equation 510 provides a slope value 514 that can be evaluated to determine whether the corrected quantitative indication 506 falls within the sufficient linear dynamic range of the flow cytometer 100 (i.e., Figure 5That is, the fit of the corrected quantitative indication 506 can be compared to an acceptable dilution quality parameter at least in part by comparing the calculated slope value 514 of the trend line 508 relative to an idealized slope value of -1. Specifically, a range of acceptable slope values can be user-defined or can be user-definable. Accordingly, a slope value 514 that falls within the range of acceptable slope values can indicate an acceptable dilution quality parameter for the corrected quantitative indication 506, indicating that the corrected quantitative indication used to generate the fit falls within the dynamic range of the instrument. However, a calculated slope value 514 that falls outside the range of acceptable slope values can result in a dilution fit notification, as described in more detail below.
[0060] Additionally, the coefficient of determination (or R) of the trend line 508 of the plotted points relative to the corrected quantitative indication may also be provided. 2 value)512. R 2 Values 512 may also include a dilution quality parameter, which may be used to analyze trend line 508. 2 Value 512 may provide a quantitative characterization of the amount of change in quantitative indication of correction 506 relative to trend line 508. In other words, R 2 The value 512 may provide a quantitative indication 506 of how well the fit describes the correction. 2 The closer R is to 1, the better the fit of trend line 508 is to the plotted corrected dilution factor 506. In this regard, R 2 Value 512 can also provide a dilution quality parameter, which can be used to assess the acceptability of the fit. That is, it can provide an acceptable R 2 Therefore, it falls within the acceptable R 2 The calculated R value is within the range of 2 Value 512 may indicate an acceptable dilution quality parameter for the corrected quantitative indication 506, which indicates that the corrected quantitative indication used to generate the fit falls within the dynamic range of the instrument. 2 Values outside the range of calculated R 2 A value of 514 may result in a fit notification, as described in more detail below.
[0061] Further with respect to evaluating the acceptability of the fit calculated for the corrected quantitative indication 506, Figure 7 A graph 600 of another example set of corrected quantitative indications 606a, 606b, 606c, and 606d is illustrated. Again, a trend line 508 has been calculated, corresponding to the fit of the corrected quantitative indication 606. As can be appreciated, the calculated slope value 514 of the trend line 508 is approximately -0.7, indicating a deviation from the idealized value of -1. Figure 7In the exemplary case presented in , this slope value 514 is deemed to fall outside the range of acceptable slope values, resulting in a fit notification because the dilution quality parameter of the slope is not an acceptable dilution quality parameter for the purposes of this example. 2 The value 512 is from R 2 The idealized curve 500 decreases as the value approaches the idealized value 1. Accordingly, R in this case 2 The value 512 also falls within the acceptable R 2 The value is outside the range that makes R 2 A value of 512 also results in a fit notification.
[0062] Furthermore, the fitted dilution quality parameters of the corrected quantitative indications 606a, 606b, 606c, and 606d that do not have acceptable dilution quality parameters may indicate that at least one of the flow cytometry results corresponding to the corrected quantitative indications 600 falls outside the dynamic range of the flow cytometer 100, such that the results do not exhibit sufficient linearity. Specifically, the fit of the corrected quantitative indications 606 may indicate that the accuracy of at least one of the corresponding flow cytometer results is impaired due to an instrument error in the result caused by one of the fluid samples at a concentration outside the dynamic range of the flow cytometer 100 for the fluid sample properties under investigation. As can be appreciated, such an error is likely to occur for the flow cytometer results (and, therefore, the corresponding corrected quantitative indications 606) corresponding to the maximum dilution or minimum dilution in the provided data set, because these values are most likely to be at or outside the boundaries of the dynamic range of the instrument. In the curve 600, this corresponds to the corrected quantitative indication 606a representing the minimum dilution of the data set or the corrected quantitative indication 606d representing the maximum dilution of the data set. Accordingly, one or both of the corrected quantitative indication 606a corresponding to the maximum dilution and / or the corrected quantitative indication 606d corresponding to the minimum dilution of the data set may be removed from the calculated trend line 508 to determine whether the resulting dilution quality parameters of the remaining corrected quantitative indications 606 correspond to acceptable dilution quality parameters.
[0063] Further references Figure 8 , presents a curve 700 in which the corrected quantitative indication 606a has been removed from the calculated fit (e.g., as an outlier), so that an updated calculation of the trend line 508 is provided. As can be appreciated, after removing the corrected quantitative indication 606a, the slope value 514 of the trend line 508 returns to near ideal, and R 2 The value 512 also increases to be close to ideal. In this case, the slope value 514 and R 2Both values 512 may correspond to acceptable dilution quality parameters such that the fits of the remaining corrected quantitative indications 606b, 606c, and 606d may be confirmed (or validated for data analysis purposes) as representing sufficiently linear results indicating that the corrected quantitative indications are acceptably within the dynamic range of the flow cytometer instrument.
[0064] While the above contemplates evaluation of the corrected quantitative indication 606 to determine whether the corrected quantitative indication 606 is within the dynamic range of the instrument, determining the optimal dilution range for a given screening sample inventory may involve further isolation of a range of concentrations over which the flow cytometer 100 exhibits further accuracy. That is, a flow cytometer may exhibit an absolute range over which results may be generated, which may not result in a linear relationship of flow cytometric results over the entire absolute range (i.e., there may be errors for samples at high and / or low dilutions in the absolute range). A flow cytometer may also have a dynamic range for a given set of samples where the results (or corrected results) exhibit sufficient linearity to fall within the dynamic range of the instrument as determined above. Additionally, a flow cytometer may generally provide more accurate results within an optimal performance band defined relative to the particle concentration in the fluid sample being investigated. Such an optimal performance band may represent a higher performance sub-range within the dynamic range. Given the extreme sensitivity of flow cytometers, conducting flow cytometric studies of fluid samples having concentrations within the optimal performance band may provide further enhanced accurate and precise results for a given flow cytometer studying a given target sample inventory.
[0065] Therefore, returning to the reference Figure 8, the trend line 508 of the corrected quantitative indication 606 can be further used to determine a range of dilution factors that optimizes the screening sample inventory, wherein the trend line 508 reflects sufficient linearity in the data such that the corrected quantitative indication 606 is within the dynamic range of the instrument. Specifically, a lower performance concentration limit 702 and an upper performance concentration limit 704 can be defined for the flow cytometer 100, as reflected in the curve 700. The lower performance concentration limit 702 and the upper performance concentration limit 704 can be empirically determined for a given flow cytometer 100 or can be user-definable. In any aspect, the lower performance concentration limit 702 and the upper performance concentration limit 704 can define a concentration sub-range within the dynamic range over which the performance of the flow cytometer 100 exhibits improved accuracy. In turn, the lower performance concentration limit 702 can be used to determine a point at which the trend line 508 of the data in the dynamic range of the instrument corresponds to the lower performance concentration limit 702. For data within the dynamic range of the instrument, the dilution factor at which the lower performance concentration bound 702 intersects the trend line 508 can define an upper optimized dilution factor bound 706 for the optimized dilution factor range. Likewise, the dilution factor at which the upper performance concentration bound 704 intersects the trend line 508 can define a lower optimized dilution factor bound 708 for the optimized dilution factor range. Thus, the optimized dilution factor range can correspond to a range between the lower optimized dilution factor bound 708 and the upper optimized dilution factor bound 706, as determined by analyzing the upper performance concentration bound 704 and the lower performance concentration bound 702 with respect to the trend line 508 for data determined to be within the dynamic range of the instrument.
[0066] Furthermore, and also with reference to Figure 3 , the foregoing analysis can be used to determine an optimal dilution factor range for a given screening sample fluid inventory 390. Such analysis can be performed by the screening assay module 360 of the flow cytometry system 300 in conjunction with Figure 9-16 The graphical user interface 380 may include several screens that may be presented to the user, generally relating to: the selection of flow cytometry results, either for screening analysis by the screening assay module 360 or for analysis by the titer assay module 370; Figure 9-10 The titer analysis in the result list screen 800 shown in FIG. Figure 11-14 Control and interaction with the screening assay module 360 for screening analyses in the screening assay screen 900 shown in FIG. 9; and Figure 15-161000 and the titer analysis in the titer assay screen 1000 shown in the figure. In addition, each screen of the graphical user interface 380 can display a screen selection portion 820. The screen selection portion 820 can provide a label, and the label corresponds to a different corresponding screen that can be used to select a given screen of the graphical user interface 380. In this regard, the screen selection bar 820 can include an analysis label 822, a result label 824, a screening label 826, and a titer label 828. The analysis label 822 can be manipulated by the user in conjunction with the operation of the flow cytometer during the flow cytometry study to monitor the operation of the flow cytometer 100, and will not be discussed in detail herein. The graphical user interface 380 can also include an instrument control panel 810, which can include various interfaces for controlling the operation of the flow cytometer 100.
[0067] Fig. 9 A result list screen 800 of the graphical user interface 380 is depicted. The result list screen 800 may include a result list 850 that includes a list of flow cytometry results from the flow cytometry results database 310. As described above, the screening target fluid sample 392 may be prepared at each of a plurality of dilutions of the screening sample fluid inventory 390. Additionally, a dye or coloring may be added to each screening target fluid sample 392 that may be used in the detection of target particles having a particular particle attribute. In an embodiment, the plurality of screening target fluid samples 392 may include a dilution series of the screening sample fluid inventory 390 that is diluted to a plurality of dilution factors (e.g., a plurality of different dilution factors). In an embodiment, the dilution series may include a ten-fold dilution series of the screening sample fluid inventory 390, such that the screening target fluid sample 392 is provided by dilutions that increase by a factor of ten (e.g., 10:1, 100:1, 1,000:1, etc.). In at least one embodiment, a single screening target fluid sample 392 may be prepared for each of the plurality of dilution factors. That is, in at least one embodiment, multiple copies of the screening target fluid sample 392 at a given dilution may not need to be subjected to flow cytometric study, thereby reducing the number of fluid samples that need to be studied and providing the benefits discussed above. The flow cytometric results of the multiple screening target fluid samples 392 can be provided to and stored in the flow cytometer results database 310 so that they are reflected in the results list 850. As shown in Fig. 9 As can be appreciated, the selection of a given result from the result list 850 can expand the given result to provide additional information and / or options for the given result. For example, an option can be provided to allow a user to comment on the result or provide an electronic signature.
[0068] In addition, one or more screening blank control fluid samples 398 can be prepared and subjected to flow cytometric research using the flow cytometer 100. One or more screening blank control fluid samples 398 can contain one or more fluid samples corresponding to multiple screening target fluid samples 392. Therefore, one or more screening blank control fluid samples 398 can have properties similar to multiple screening target fluid samples, but can be substantially or completely free of the target particles of interest to be studied. The flow cytometric results generated for the screening blank control fluid samples 398 can reflect the background noise detected by the flow cytometer 100 rather than the actual particle count, so that the screening blank control fluid samples 398 can be used to prepare a quantitative indication of correction, as described above. In an embodiment, one or more screening blank control fluid samples 398 can be a blank sample matrix of multiple screening target fluid samples 392 of the same type, without the target particles of interest being studied by the flow cytometric research, but have similar properties and preparation in other aspects, such as containing dyes or coloring used in the flow cytometric research. Multiple screening blank control fluid samples 398 can be provided with a dilution corresponding to each of the multiple dilutions provided in the multiple screening target fluid samples 392. In this regard, the correspondence between a plurality of screening target fluid samples 392 and screening blank control fluid samples 398 can relate to the common dilution of each sample. In another embodiment, one or more screening blank control fluid samples 398 can include solution buffer and / or other reagent fluids, replace blank sample inventory matrix fluid (for example, when blank inventory sample matrix fluid is unavailable). In this regard, corresponding dilution can not be provided, and single screening blank control fluid sample 398 can be subjected to flow cytometry research to determine the solution buffer used in the test and / or any dye or the background noise associated with coloring. Once the flow cytometry research of one or more screening blank control fluid samples 398 is carried out, the flow cytometer result of screening blank control fluid sample 398 can be provided to flow cytometer result database 310, and can be reflected in the result list 850.
[0069] The results list 850 may include several data columns related to data parameters of the flow cytometry results, which are provided as row entries in the results list 850. For example, the columns may reflect any information of the flow cytometry results contained in the flow cytometry results database as described above, including but not limited to a sample name column 852, a dilution factor column 854, a particle count result column 856, a titer result column 858 (showing particle concentration), an acquisition date / time column 860, an instrument identifier column (not shown), an operator column (not shown), and other data columns that may be related to the flow cytometry study, such as individual detection channel counts and irradiation detection data, such as detector baseline, peak, and width. The results list 850 may be sortable according to any of the columns presented in the results list 850. In addition, additional sorting functionality may be provided through a user sort option 872, an instrument sort option 874, or a date sort option 876. In addition, an option to hide certain types of flow cytometry results may be provided.
[0070] Further references Fig.10 , the user can select a flow cytometry result from the result list 850 to designate a specific flow cytometry result for use in a screening analysis performed by the screening assay module 360 or a titer analysis performed by the titer assay module 370. With respect to the selection of a flow cytometry result for use by the screening assay module 360, the user can select one or more flow cytometry result entries from the result list 850 by navigating to a result designation menu 878, which contains a screening selection submenu 880 that allows selection of a screening control group selection 882 or a screening target group selection 884. That is, a result selected from the result list 850 can be selected by the user to belong to the screening control group by selecting a flow cytometry result and selecting the screening control group selection 882. Similarly, a result selected from the result list 850 can be selected by the user to belong to the screening target group by selecting a flow cytometry result and selecting the screening target group selection 884.
[0071] Further references Fig.11 , depicts a screening assay screen 900 that may be presented to a user upon selecting the filter tab 826 from the screen selection bar 820. The screening assay screen 900 may include a filter control group list 902 populated with a filter control group 906 selected by the user using a filter control group selection 884. The screening assay screen 900 may also include a filter target group list 904 populated with flow cytometry results including a filter target group 908 selected from the results list 850 in the results screen 800 using the target filter group selection 884.
[0072] Upon selection of the screening control group 906 and the screening target group 908, the screening control group 906 and the screening target group 908 may be used to perform one or more of the determinations or calculations described above with respect to determining the dynamic range of the instrument relative to the selected screening target group 908. Such calculations may be performed automatically when the screening target group 904 and the screening control group 906 are populated or may require the user to initiate the calculation by selecting a calculation button 910. In this regard, Fig.11 An example of a screening assay screen 900 is depicted in which a screening control group 906 and a screening target group 908 have been selected, but the calculation of the optimized dilution factor range has not yet been calculated. Fig.12 , which depicts a screening assay screen 900 in which an optimized dilution factor range calculation has not yet been performed (eg, automatically or by selecting a calculate button 910). The selection of automatic calculation or user-initiated calculation may be configured in the settings menu of the graphical user interface 380.
[0073] Continue to refer Fig.12 In conjunction with the above calculations and analyses to determine the optimal dilution factor range, the screening assay screen 900 may also include a curve area 916 in which a corrected quantitative indication based on the screening target group 908 and the screening control group 906 is displayed to the user. That is, the screening assay module 360 may be operable to calculate a corrected quantitative indication of particles for each of the screening target fluid samples of the screening target group 908 based on a corresponding one of the screening control groups 906. Each of the screening target groups 908 may also be displayed in the corrected quantification column 912 of particles in the screening target group list 904.
[0074] Additionally, the screening assay module 360 can determine whether the selected screening control group 906 contains corresponding results for the screening target group 908. That is, the screening assay module 360 can examine the control samples provided at dilutions corresponding to each dilution of the target fluid sample of the screening target group 908. If there is no correspondence (e.g., a screening control fluid sample is selected for which there is no corresponding screening target fluid sample, or a screening target fluid sample is selected for which there is no screening control fluid sample), the screening assay module 360 can generate a corresponding notification, which can trigger the data notification indicator 924 to be displayed, such as Fig.13 That is, a data notification indicator 924 may be provided in the context of any data notification being presented regarding the operation of the screening assay module 360. Further, selecting the data notification indicator 924 may result in displaying a data notification detail list 926, such as Fig.14As shown. Data notification detailed list 926 can include a detailed list of all data notifications presented, such as the corresponding notification discussed above or any further data notification described in the following description. Corresponding notification can be provided as a warning notification or warning provided to the user, indicating a lack of correspondence. This can allow the user to solve the lack of correspondence by reviewing and / or revising the selected screening control group 906 and / or screening target group 908. For example, any one of the screening control fluid sample in the screening control group 906 or the screening target fluid sample in the screening target group 908 can be highlighted in the screening control group list 902 or the target group list 904 (for example, by offsetting the background color or changing the font color, size, or other formats), indicating that no corresponding result is provided. Data notification can be informative or can require the action of the user to solve the problem that causes notification before determining the optimal dilution factor range. For example, the user can be required to return to the result list 850 and select the appropriate corresponding value of the missing. In the case where the corresponding notification can be a warning, the user can also choose to continue without solving the problem that causes notification. Alternatively, the corresponding notification may result in a fault in the screening assay module 360 that precludes further calculation of the optimized dilution factor range until and unless the condition that generated the corresponding notification is resolved by the user.
[0075] In certain embodiments as above, one or more screening blank control fluid samples can use sample dilution buffer and / or other reagent liquids and do not use sample inventory matrix preparation.In this case, may not need to screen the direct correspondence between control group 906 and screening target group 908, because screening blank control fluid sample may not have the corresponding dilution to a plurality of screening target fluid samples.In this regard, can be selected by the user to control corresponding overwrite selection 914, it will overwrite any corresponding notification, and make screening assay module 360 will be used for correcting each in a plurality of screening target fluid samples of screening target group 908 from the given control sample result of screening control group 908.
[0076] The screening assay module 360 may also calculate a corrected quantitative indication 912 for each of the screening target groups 908. This may include subtracting the flow cytometry results of the screening control group 906 from the corresponding one of the screening target groups 908. Furthermore, the screening assay module 360 may determine whether any resulting corrected quantitative indication 912 is negative, and may provide a corrected quantitative indication notification in the event of any negative corrected quantitative indication 912 being calculated. For example, the corrected quantitative indication notification may result in a data notification indication 924. Details of the corrected quantitative indication notification may also be provided in a data notification detail list 926, if present. The corrected quantitative indication notification may be a warning notification, in which the indication of the notification is presented to the user for informational purposes, or may result in a fault, which precludes further processing by the screening assay module 360. In addition, the negative corrected quantitative indication 912 may be highlighted in the target group list 904 by a highlighted value and / or a value provided in a specific text color, size, format, etc.
[0077] Once the corrected quantitative indication 912 has been calculated for each of the screening target groups 908, the corrected quantitative indication 912 can be plotted in the curve area 916. In addition, a trend line 918 corresponding to the linear regression fit of the corrected quantitative indication 912 can be displayed. An optimized dilution factor range display 920 can be provided, which reflects the slope 514 of the trend line 918, as described above with respect to the analysis for determining the optimized dilution factor range. In addition, the R value can also be provided in the optimized dilution factor range display 920. 2 The user may be prompted to review the curve area 916 and / or the optimized dilution factor range display 920 to verify the dilution quality parameter or other value displayed therein. This may include the user being prompted to check the slope value 514 or R 2 The value 512 is used to determine whether the resulting fit of the corrected quantitative indication is within an acceptable range. The acceptable range can be displayed in the optimized dilution factor range display 920, or the value of the optimized dilution factor range itself can be highlighted or otherwise indicated as acceptable or unacceptable for a given acceptable range defined for the dilution quality parameter of the fit. For example, the value of the optimized dilution factor range displayed in the optimized dilution factor range display 920 can be highlighted in a specific color to specify whether the value is acceptable or unacceptable. For example, the value can be highlighted green for an acceptable value, or can be highlighted red for an unacceptable value. Additionally or alternatively, the text color can be used as an indication of an acceptable or unacceptable value in any one of the screens described herein. The screening assay module 360 can define or allow the user to define (e.g., via input from the graphical user interface 380) the definition of an acceptable range for a dilution quality parameter (e.g., an acceptable range for slope and / or R 2918). Alternatively or in addition, if the dilution quality parameter of the corrected quantitative indication 912 is not within the corresponding acceptable range, the trend line 918 may not be generated within the curve area 916. In addition, if the dilution quality parameter is not within the acceptable range, a fitting notification may be presented to the user. The fitting notification may include displaying to the user, such as highlighting or other indications, indicating that the dilution quality parameter is outside the acceptable range. The fitting notification may also result in a list of fitting notifications in a data notification indicator 924 and a data notification detail list 926. In this regard, the fitting notification may be a warning notification that allows the user to override the notification and continue calculating the optimized dilution range. Alternatively, the optional dilution range may not be displayed until and unless it is determined that the dilution quality parameter is within the acceptable range (e.g., by deleting one or more of the corrected quantitative indications 912 from use in calculating the trend line 918). In addition, an idealized trend line 922 may be provided in the curve area 916 to assist the user in reviewing the trend line 918.
[0078] Once it has been confirmed that trend line 918 reflects the dynamic range of the instrument, the optimized dilution factor range can be presented to the user in the optimized dilution factor range display 920. As described above, the optimized dilution factor range can extend between the lower dilution factor limit corresponding to the upper performance concentration limit and the upper dilution factor limit corresponding to the lower performance concentration limit. The upper performance concentration limit and the lower performance concentration limit can be provided together with the corresponding dilution factors listed related thereto in the optimized dilution factor range display 920. Alternatively, the rounding dilution factor including the user's convenient dilution can be presented in the optimized dilution factor range display 920. That is, the lower dilution factor limit and the upper dilution factor limit of the optimized dilution factor range can correspond to the dilution factor that is relatively convenient to prepare. Therefore, the screening assay module 360 can select one or more convenient dilution factors in the dilution factor range to be presented to the user as the optimized dilution factor. This can include the rounding dilution factor in the optimized dilution factor range. As an example, if the optimized dilution factor range is between 88 and 242, a rounded dilution factor of 100 or 200 may be suggested to the user as a convenient dilution factor that allows for easier optimization of the target fluid sample preparation. In this regard, the optimized dilution factor range need not span between upper and lower limits, but may be provided as a single dilution factor value as described above.
[0079] Once the optimization dilution factor range has been presented to the user, the titer assay module 370 can be used to perform titer analysis. This can include preparing an optimization target fluid sample 396 with a dilution in the target dilution range determined by the screening assay module 360. In this regard, the optimization target fluid sample 396 can have a dilution factor that falls within the optimization dilution factor range. In an embodiment, the screening assay module 360 can present instructions about preparing the optimization target fluid sample 396 to the user so that the optimization target fluid sample 396 falls within the optimization dilution factor range. In any respect, the optimization target fluid sample 396 can be subjected to the flow cytometry research performed by flow cytometry 100, and the flow cytometry results of the optimization target fluid sample 396 can be provided to the flow cytometry results database 310. In addition, one or more optimization blank control fluid samples 399 can also be prepared and subjected to flow cytometry research. The optimization blank control fluid sample 399 can be similar to the screening blank control fluid sample, which can be prepared using a blank fluid matrix of a corresponding sample stock at a corresponding dilution factor for optimizing the target fluid sample (e.g., to optimize a dilution within a target dilution range) and without the target particles. The optimization blank control fluid sample 399 can be prepared without using a corresponding sample stock fluid matrix and can instead contain a sample dilution buffer and / or other reagent liquids and instead have a corresponding dye or coloring provided therewith to provide a blank control fluid sample with respect to the optimization target fluid sample 396.
[0080] Furthermore, the user can select the optimization target group and the optimization control group from the result list 850 by selecting the result tab 824 to use the Fig.10 800 shown in the result screen 800. The titer selection submenu 886 of the result designation menu 878 can be used to designate the flow cytometry results from the result list 850 as an item of the optimization target group of the optimization target fluid sample or an item of the optimization control group, the optimization control group including one or more optimization blank control fluid samples similar to those discussed above regarding the selection of the screening target group and the screening control group for the operation of the screening assay module 360. That is, the titer selection submenu 886 can also have the optimization control group selection and the optimization target group selection in the titer selection submenu 886, which can be used to designate the optimization control group and the optimization target group, respectively, from the result list 850.
[0081] Further references Figure 15-16, depicting a titer assay screen 1000. The titer assay screen 1000 may be accessed by selecting the titer tab 828 in the screen selection bar 820. The titer assay screen 1000 may include an optimized control group list 1002 reflecting an optimized control group 1008 selected by a user from the results list 850 and an optimized target group list 1004 reflecting an optimized target group selected by a user from the results list 850. The titer assay module 370 may be operable to calculate a particle titer result for the target sample inventory based on the optimized target group 1006 and the optimized control group 1008 selected by the user. The particle titer result may be displayed in a titer result section 1010 of the titer assay screen 1000. The particle titer result may include an average titer 1012 of the target sample inventory 394, a standard deviation 1014 of the flow cytometry results of the optimized target group 1006, and a coefficient of variation 1016 of the particle titer result. Average titer 1012 may be an average concentration of target particles in the target sample inventory determined from optimized target set 1006 .
[0082] In conjunction with the determination of the particle titer results 1010, the potency assay module 370 can calculate a corrected quantitative indication 1026 for the optimized target set 1006 based on the optimized control set 1002. This can include subtracting the average result of the optimized control set 1002 from the flow cytometry results of the optimized target set 1004. As in the case of operation of the screening assay module 360, if the potency assay module 370 determines that any corrected quantitative indication 1026 for the optimized target set 1006 is negative, a corrected quantitative indication notification can be presented, which can notify the user of the circumstances that generated the notification and / or exclude the determination of the particle titer results 1010. For example, if Fig.16 As shown in FIG. 100 , in the case where data notifications are being presented regarding the operation of the potency assay module 370, a data notification indicator 928 may also be provided in the potency assay screen 1000. Although not shown, a data notification indicator 926 regarding the operation of the potency assay module 370 may also be provided when the data notification indicator 926 of the potency assay screen 1000 is selected. Fig.14 The data notification details list in the potency assay screen 1000 may provide data notification details for the operation of the potency assay module 270 .
[0083] In addition, the titer assay module 370 can verify that the dilution factors of all optimized control groups 1008 and optimized target groups 1006 are within the optimal dilution range established by the screening assay module 360. In the case where the result is outside the optimized dilution factor range, a dilution factor notification can be presented about the optimized control group 1008 or optimized target group 1006 items outside the optimized dilution factor range, and a data notification indicator 926 can be displayed. In addition, the value outside the acceptable range can be highlighted, or the font color, size or format can be changed to indicate the data notification as described above. In addition, an absolute limit on the dilution can be established, which can be a wider range than the optimized target range. If any optimized control group 1008 or optimized target group 1006 is outside the absolute dilution factor range, a dilution factor notification can also be presented.
[0084] Additionally, it will be appreciated that the average titer result 1012 may be based on a dilution factor for the optimized target set 1006 (e.g., an extrapolation of the particle quantification indication from the diluted sample to the particle results in the undiluted target sample fluid inventory 394). In this regard, the potency assay module 370 may determine or calculate an effective dilution factor 1028 to determine the average titer 1012. The effective dilution factor may be automatically populated based on the dilution factor for the optimized control set 1006.
[0085] The titer result section 1010 may also include calculated sample qualification limits (SQL) 1018. SQL 1018 may be determined based on the flow cytometry results of the optimization target group 1006 and the optimization control group 1008. SQL 1018 may correspond to limits at which the sample results may be determined in a given matrix of the sample results with appropriate precision and accuracy. SQL 1018 may be determined based on the average results of the optimization control group 1008, the observed variability of the optimization target group 1006 (e.g., as reflected in the standard deviation of the optimization control group) and the expected confidence 1020. The expected confidence 1012 may be selectable by the user in the titer result section 1010. In this regard, SQL 1018 may be used to determine whether the sample results are statistically significantly greater than the background signal from the sample matrix. SQL 1018 may be calculated based on the average of the optimization control group results 1008. Specifically, the standard deviation of the optimization control group 1008 may be calculated. A confidence interval may also be calculated based on the standard deviation of the optimized control group 1008. The confidence interval may be the standard deviation of the optimized control group 1008 multiplied by an appropriate confidence value, as determined from a t-distribution table. The confidence value may be determined based on the degrees of freedom of the data (e.g., a value less than one of the number of copies of the optimized control group 1008) and based on the selected confidence level 1020. The resulting confidence value may be added to the mean of the measurements of the optimized control group to define the SQL 1018.
[0086] like Fig.17 , SQL 1018 is plotted in the graph as an error bar with respect to the optimized blank control fluid sample result 1022. As can be appreciated, corresponding to Fig.12 1024 for the optimized blank control fluid sample result 1022 depicted in FIG. 10 is provided outside of the SQL 1018 as shown with respect to the optimized blank control fluid sample result 1022. However, if the optimized target fluid sample result 1024 is outside of the SQL 1018 defined relative to the corresponding optimized blank control fluid sample result 1022, then an SQL notification can be provided on the graphical user interface 380. Additionally, the SQL notification can exclude the calculation of the average particle titer in the particle titer results section.
[0087] The titer assay module 370 may perform other validation of the data used to calculate the particle titer results and / or the particle titer results themselves. With respect to the latter, a titer notification may be provided if any particle titer result 1010 is outside of defined acceptable limits, which may be user-provided or user-definable for any of the following: the mean titer 1012 of the target sample inventory 394, the standard deviation 1014 of the flow cytometry results of the optimized target set 1006, and the coefficient of variation 1016 of the particle titer results.
[0088] Although the present invention has been illustrated and described in detail in the drawings and the foregoing description, such illustration and description should be considered exemplary rather than restrictive. For example, certain embodiments described above may be combined with other described embodiments and / or arranged in other ways (e.g., processing elements may be executed in other orders). Therefore, it should be understood that only preferred embodiments and variations thereof are shown and described, and it is desired to protect all changes and modifications that fall within the spirit of the present invention.
[0089] Exemplary implementation combinations
[0090] Some other contemplated embodiments of implementation combinations of aspects of the present disclosure, with or without additional features disclosed above or elsewhere herein, are summarized in the exemplary numbered combinations presented below:
[0091] 1. A flow cytometric method for quantifying target particles having specific particle properties in a target sample fluid inventory using a flow cytometer, the flow cytometer being operable to flow the fluid sample through a flow cytometric investigation zone subjected to investigation excitation radiation, and to detect and measure response radiation from the investigation zone, and to determine and output a flow cytometric result, the flow cytometric result comprising a quantitative indication of the target particles in each of the fluid samples, the method comprising:
[0092] subjecting a screening target set of screening target fluid samples, said screening target fluid samples comprising a dilution series of a screening sample fluid stock diluted at a plurality of dilution factors, and optionally having only one said screening target fluid sample at each said dilution factor, to a first flow cytometry evaluation, wherein said subjecting to a first flow cytometry evaluation comprises:
[0093] causing each of the screening target fluid samples to flow through an investigation zone of the flow cytometer and subjecting each of the screening target fluid samples to the investigation excitation radiation in the investigation zone,
[0094] detecting the responsive radiation from the investigation zone and generating a flow cytometry result for each of the screened target fluid samples, the flow cytometry result comprising a quantitative indication of target particles in the screened target fluid sample, and
[0095] storing the flow cytometry results of the screening target group in a computer memory, the memory having stored therein a screening assay module and a titer assay module, the screening assay module being accessible and executable by a processor, and the titer assay module being accessible and executable by the processor;
[0096] executing the screening assay module by the processor, wherein the executing the screening assay module comprises:
[0097] calculating a corrected quantitative indication for each of at least a plurality of portions of the screening target fluid sample, comprising comparing a first selected flow cytometry result of the screening target set from the memory to a corresponding second selected flow cytometry result of a screening control set selected from the memory, the screening control set comprising at least one screening blank control fluid sample corresponding to the screening target set, and adjusting the quantitative indication of the first selected flow cytometry result to the corrected quantitative indication based at least in part on the comparison, and
[0098] determining an optimized sample dilution factor range for screening the inventory fluid sample based on analysis of the corrected quantitative indication, and storing the optimized sample dilution factor range in the memory;
[0099] subjecting an optimized target set of optimized target fluid samples, each of which comprises the target sample fluid stock diluted to an optimized sample dilution factor within the range of optimized sample dilution factors, to a second flow cytometry evaluation, wherein the subjecting comprises:
[0100] flowing each of the optimized target fluid samples through an investigation zone of the flow cytometer and subjecting each of the optimized target fluid samples to the investigation excitation radiation in the investigation zone,
[0101] detecting the responsive radiation from the investigation region and generating the flow cytometry result for each of the optimized target fluid samples, the flow cytometry result comprising a quantitative indication of target particles of the optimized target fluid sample, and
[0102] storing the flow cytometry results of the optimized target group in the memory;
[0103] Executing the potency assay module with the processor, wherein executing the potency assay module comprises:
[0104] accessing the optimized target set of flow cytometry results in the memory, and
[0105] Using the flow cytometry results of the optimized target set, calculating particle titer results for the target sample fluid inventory, optionally including a calculated concentration of the target particles in the target sample fluid inventory; and
[0106] Particle titer results for the target sample fluid inventory are stored in the memory.
[0107] 2. The method according to exemplary combination 1, further comprising:
[0108] A results list corresponding to the flow cytometry results stored in the memory is displayed on a display of a graphical user interface, optionally having a user input device.
[0109] 3. The method according to exemplary combination 2, further comprising:
[0110] A first screening selection is received from a user by a user input device of the graphical user interface, the first screening selection comprising the first selected flow cytometry results of the plurality of portions of the screening target fluid sample from the results list.
[0111] 4. The method of exemplary combination 3, wherein said performing said screening assay module further comprises:
[0112] Based on the first screening segment selected by the user from the results list, the memory is accessed to retrieve the first selected flow cytometry results for the plurality of portions of the screening target fluid sample.
[0113] 5. The method according to any one of exemplary combinations 2-4, further comprising:
[0114] A first titer selection is received from the user by a user input device of the graphical user interface, the first titer selection comprising a flow cytometry result of the optimized target fluid sample selected by the user from the list of results.
[0115] 6. The method according to exemplary combination 5, wherein the performing the potency assay module further comprises:
[0116] Based on the first titer selection selected by the user from the results list, the memory is accessed to retrieve flow cytometry results for the optimized target fluid sample.
[0117] 7. The method according to exemplary combination 5 or exemplary combination 6, further comprising:
[0118] Flow cytometry results for at least one screening blank control fluid sample of the screening control set are stored in the memory.
[0119] 8. The method according to any one of exemplary combinations 1-7, further comprising:
[0120] subjecting the screening control set including the at least one screening blank control fluid sample to a third flow cytometry evaluation, the subjecting the screening control set including the at least one screening blank control fluid sample to a third flow cytometry evaluation comprising:
[0121] flowing each of the screening blank control fluid samples through the flow cytometer investigation zone and subjecting each of the screening blank control fluid samples to the investigation excitation radiation in the investigation zone, and
[0122] The responsive radiation from the investigation region is detected, and the flow cytometry result is generated for each of the screening blank control fluid samples, the flow cytometry result comprising a quantitative indication of the target particles of the screening blank control fluid sample.
[0123] 9. The method according to exemplary combination 8, further comprising:
[0124] A second screening selection is received from a user by a user input device of the graphical user interface, the second screening selection comprising flow cytometry results for the at least one screening blank control fluid sample from a list of results displayed on the graphical user interface.
[0125] 10. The method of exemplary combination 9, wherein said performing said screening assay module further comprises:
[0126] Based on the second screening segment selected by the user from the results list, the memory is accessed to retrieve a second selected flow cytometry result of the at least one screening blank control fluid sample.
[0127] 11. The method according to any one of exemplary combinations 1-10, wherein the performing the potency assay module further comprises:
[0128] The particle titer results of the target sample fluid inventory are calculated using the flow cytometry results of the optimized target set and an optimized control set, the optimized control set including at least one optimized blank control fluid sample corresponding to the optimized target set.
[0129] 12. The method according to exemplary combination 11, wherein said executing said potency assay module further comprises:
[0130] Determining a sample qualification restriction (SQL) for the flow cytometry results of the optimized target group based on the flow cytometry results of the optimized control group; and
[0131] If the flow cytometry results for any one of the optimization target groups do not exceed the SQL, an indication of a SQL notification is optionally provided on a graphical user interface.
[0132] 13. The method according to exemplary combination 11 or exemplary combination 12, further comprising:
[0133] Flow cytometry results of at least one optimized blank control fluid sample of the optimized control set are stored in the memory.
[0134] 14. The method according to any one of exemplary combinations 11-13, further comprising:
[0135] subjecting the optimized control set including the at least one optimized blank control fluid sample to a fourth flow cytometry evaluation, the subjecting the optimized control set including the at least one optimized blank control fluid sample to a fourth flow cytometry evaluation comprising:
[0136] flowing each of the optimized blank control fluid samples through the investigation zone and subjecting each of the optimized blank control fluid samples to the investigation excitation radiation in the investigation zone, and
[0137] The response radiation from the investigation region is detected, and the flow cytometry result is generated for each of the optimized blank control fluid samples, the flow cytometry result comprising a quantitative indication of the target particles of the optimized blank control fluid sample.
[0138] 15. The method according to any one of exemplary combinations 11-14, further comprising:
[0139] A second titer selection is received from a user by a user input device of the graphical user interface, the second titer selection comprising the flow cytometry results of the at least one optimized blank control fluid sample from the results list displayed on the graphical user interface.
[0140] 16. The method according to exemplary combination 15, wherein said executing said potency assay module further comprises:
[0141] Based on the second valence band selected by the user from the results list, the memory is accessed to retrieve the flow cytometry results for the at least one optimized blank control fluid sample.
[0142] 17. The method of any one of exemplary combinations 1-16, wherein said performing said screening assay module further comprises:
[0143] first determining whether a first condition exists in which a flow cytometry result of the screening blank control fluid sample corresponding to each of the screening target fluid samples of a plurality of portions of the screening target fluid samples exists; and
[0144] When it is determined during said first determination that such a first condition does not exist, a corresponding notification is optionally provided on a graphical user interface.
[0145] 18. The method of any one of exemplary combinations 1-17, wherein said performing said screening assay module further comprises:
[0146] a second determining whether there is a second condition that each said quantitative indication of a second selected flow cytometry result of said screening control set is greater than a corresponding said quantitative indication of a first selected flow cytometry result of said screening control set; and
[0147] When it is determined during the second confirmation that such a second condition does not exist, an indication of a quantitative correction notification is optionally provided on a graphical user interface.
[0148] 19. The method of any one of exemplary combinations 1-18, wherein in said performing said screening assay module said determining an optimized sample dilution factor further comprises:
[0149] A fit of the corrected quantitative indication is calculated relative to a plurality of dilution factors, wherein portions of the screening target fluid sample of the first selected flow cytometry result represent the plurality of dilution factors.
[0150] 20. The method of exemplary combination 19, wherein said performing said screening assay module further comprises:
[0151] A curve of fit of the corrected quantitative indication relative to the corresponding multiple dilution factors is displayed on a graphical user interface, optionally with the fit of the plotted points in the curve displayed relative to the plotted corrected quantitative indication, and optionally the fit is plotted as a linear trend line.
[0152] 21. The method of exemplary combination 20, wherein said performing said screening assay module further comprises:
[0153] An idealized trend line on the curve is displayed on the graphical user interface.
[0154] 22. The method of exemplary combination 20 or exemplary combination 21, wherein said performing said screening assay module further comprises:
[0155] If screening the plurality of portions of the target fluid sample does not generate a graphable result, a graphical notification indication is provided.
[0156] 23. The method of any one of exemplary combinations 19-22, wherein said performing said screening assay module further comprises:
[0157] The fit is compared relative to one or more dilution quality parameters, wherein the optimized sample dilution factor range is determined after the fit meets acceptable dilution quality parameters.
[0158] 24. The method of exemplary combination 23, wherein said performing said screening assay module further comprises:
[0159] If the fit of the plurality of portions of the screened target fluid sample does not meet acceptable dilution quality parameters, an indication of a fit notification is provided.
[0160] 25. The method of exemplary combination 22 or exemplary combination 23, wherein said calculating the fit comprises determining a linear regression fit relative to a logarithmic transformation of the corrected quantitative indication and the plurality of dilution factors.
[0161] 26. A method according to exemplary combination 25, wherein the one or more dilution quality parameters include a quantitative characterization of the linear regression fit.
[0162] 27. The method of exemplary combination 25 or exemplary combination 26, wherein said performing said screening assay module further comprises:
[0163] The linear regression fit is expressed as a trend line relative to the corrected quantitative indication and the logarithmic transformation of the plurality of dilution factors, and wherein the dilution quality parameter comprises a slope and a coefficient of determination of the trend line.
[0164] 28. The method of any one of exemplary combinations 23-27, wherein the acceptable dilution quality parameters comprise an acceptable slope value of a linear trend line and an acceptable coefficient of determination of the linear trend line.
[0165] 29. A method according to exemplary combination 28, wherein the acceptable slope value is within a predetermined range of acceptable slope values, and the acceptable determination coefficient value is within a predetermined range of acceptable determination coefficients.
[0166] 30. A method according to exemplary combination 28 or exemplary combination 29, wherein the optimized sample dilution factor range is a sub-range within the range of multiple dilution factors for multiple portions of the screened target fluid sample, wherein the slope value is within a predetermined range of acceptable slope values, and the determination coefficient is within a predetermined range of acceptable fit determination coefficient values.
[0167] 31. The method of any one of exemplary combinations 28-30, wherein the optimized sample dilution factor range is defined between an upper optimized dilution factor limit and a lower optimized dilution factor limit, wherein the upper optimized dilution factor limit corresponds to a dilution value on the linear trend line corresponding to a lower optimized performance concentration limit, and the lower optimized dilution factor limit corresponds to a dilution value on the linear trend line corresponding to the upper optimized performance concentration limit; and
[0168] Optionally, the lower optimal performance concentration limit is at least 10 6.5 Particles, preferably at least 10 per ml 6.7 particles, more preferably at least 10 per ml 6.9 particles, and even more preferably at least about 10 per ml. 7.0 particles, and the upper optimization concentration limit is no more than 10 per ml 8 Particles, preferably no larger than 10 per ml 7.9 Particles, preferably no more than 10 per ml 7.8 particles, and even more preferably no more than about 10 per ml. 7.7 Particles.
[0169] 32. A method according to exemplary combination 31, wherein the lower optimal performance concentration limit and the upper optimal performance concentration limit define an optimal performance sub-range within the dynamic range of the flow cytometer determined by particle concentration; and
[0170] Optionally, the upper optimized concentration limit is not greater than 10 times the lower optimized concentration limit, preferably not greater than 10 0.8 times the lower optimized concentration limit, and more preferably no more than 10 0.5 The concentration limits were optimized as described above.
[0171] 33. A method according to any one of exemplary combinations 23-31, wherein the comparing the fits further comprises presenting a review prompt to a user to prompt the user to confirm the dilution quality parameters of the fit, and optionally the presenting comprises a visual indication presented on a graphical user interface.
[0172] 34. The method of any one of exemplary combinations 23-33, wherein said performing said screening assay module further comprises:
[0173] An acceptable dilution quality parameter input defining the acceptable dilution quality parameter is received from a user and optionally through a user input device of a graphical user interface.
[0174] 35. The method of any one of example combinations 23-34, wherein said calculating said fit further comprises:
[0175] At least one of the screened target fluid samples having a maximum of the dilution factor or a minimum of the dilution factor among the plurality of dilution factors is removed from determination of the fit, wherein the fit is determined excluding any of the corrected quantitative indications for each removed screened target fluid sample, and optionally the removal is a result of a previously proposed fit not meeting one or more acceptable dilution quality parameters.
[0176] 36. A method according to exemplary combination 35, wherein the removing is in response to user input.
[0177] 37. The method of any one of example combinations 19-24, wherein said calculating said fit further comprises:
[0178] At least one of the screened target fluid samples at a maximum of the dilution factor or a minimum of the plurality of dilution factors is removed from determination of the fit, wherein the fit is determined excluding any quantitative indication of the correction for each removed screened target fluid sample, and optionally the removal is in response to user input.
[0179] 38. A method according to any one of exemplary combinations 19-24 and 37, wherein the optimized sample dilution factor range is defined between an upper optimized dilution factor limit and a lower optimized dilution factor limit, wherein the upper optimized dilution factor limit corresponds to a dilution value on the fitting corresponding to a lower optimized performance concentration limit, and the lower optimized dilution factor limit corresponds to a dilution value on the fitting corresponding to an upper optimized performance concentration limit.
[0180] 39. The method according to exemplary combination 38, wherein the lower optimal performance concentration limit is at least 10 6.5 Particles, preferably at least 10 per ml 6.7 particles, more preferably at least 10 per ml 6.9 particles, and even more preferably at least about 10 per ml. 7.0 Particles.
[0181] 40. The method according to exemplary combination 38 or exemplary combination 39, wherein the upper optimized concentration limit is no greater than 10 8 Particles, preferably no larger than 10 per ml 7.9Particles, preferably no more than 10 per ml 7.8 particles, and even more preferably no more than about 10 per ml. 7.7 Particles.
[0182] 41. The method of any one of exemplary combinations 38-40, wherein:
[0183] The lower optimal performance concentration limit and the upper optimal performance concentration limit defining an optimal performance subrange are within a dynamic range of the flow cytometer as determined by particle concentration; and
[0184] The upper optimized concentration limit is not greater than 10 times the lower optimized concentration limit, preferably not greater than 10 0.8 times the lower optimized concentration limit, and more preferably no more than 10 0.5 The concentration limits were optimized as described above.
[0185] 42. The method of any one of exemplary combinations 1-41, wherein said performing said screening assay module further comprises:
[0186] If the optimized sample dilution factor range is outside the absolute dilution factor range of the flow cytometer, an indication of a dilution factor notification is provided, and optionally the indication of a dilution factor error includes a visual indication on a graphical user interface.
[0187] 43. The method of any one of exemplary combinations 1-42, wherein said performing said screening assay module further comprises:
[0188] An indication of the optimized sample dilution factor range is provided to the user, and optionally as a visual indication on a graphical user interface.
[0189] 44. A method according to exemplary combination 43, wherein providing an indication of the optimized sample dilution factor range includes highlighting an upper limit and a lower limit of the optimized sample dilution factor range on a display of a graphical user interface.
[0190] 45. A method according to exemplary combination 43 or exemplary combination 44, wherein providing an indication of the optimized sample dilution factor range includes optionally providing at least one optimized dilution factor value on a graphical user interface, including a rounded dilution value within the optimized sample dilution factor range.
[0191] 46. The method of any one of exemplary combinations 1-45, wherein said performing said screening assay module further comprises:
[0192] Dilution instructions are generated to prepare the optimized target set of the plurality of optimized target fluid samples within the optimized sample dilution factor range.
[0193] 47. The method of exemplary combination 46, wherein said performing said screening assay module further comprises:
[0194] The dilution instructions are optionally presented to a user on a graphical user interface for preparation of the optimized target set.
[0195] 48. The method according to any one of exemplary combinations 1-47, wherein said performing said potency assay module further comprises:
[0196] One or more potency parameters are calculated regarding the particle potency results.
[0197] 49. A method according to exemplary combination 48, wherein the one or more potency parameters include a standard deviation of the particle potency results, and optionally correspond to a standard deviation of a plurality of the concentrations of a plurality of the optimized target fluid samples.
[0198] 50. A method according to exemplary combination 48 or exemplary combination 49, wherein the one or more potency parameters include a coefficient of variation of the particle potency result, and optionally correspond to a coefficient of variation of a plurality of the concentrations of a plurality of the optimized target fluid samples.
[0199] 51. The method according to any one of exemplary combinations 48-50, wherein said executing said potency assay module further comprises:
[0200] If the valence parameter is determined to be outside of a corresponding acceptable valence parameter value range, an indication of a valence notification is optionally provided on a graphical user interface.
[0201] 51A. The method of any one of exemplary combinations 1-50, wherein said executing said potency assay module further comprises:
[0202] Each of the optimization target fluid samples of the optimization target set is confirmed to include an acceptable dilution factor.
[0203] 52. A method according to exemplary combination 51A, wherein the acceptable dilution factor is within the optimized dilution factor range.
[0204] 53. The method of exemplary combination 51A or exemplary combination 52, wherein said executing said potency assay module further comprises:
[0205] When any one or more of the flow cytometry results of the optimization target fluid samples of the optimization target group do not include the acceptable dilution factor, an indication of a titer dilution notification is provided.
[0206] 54. A method according to any one of exemplary combinations 1-53, wherein the screening control group includes a plurality of the screening blank control fluid samples, wherein at least one of the screening blank control fluid samples corresponds to each of the dilution factors of a plurality of dilution factors of the screening target fluid sample, and optionally wherein only one of the screening blank control fluid samples corresponds to each of the dilution factors of the plurality of dilution factor samples, and each of the dilution factors of the plurality of dilution factor samples corresponds to each of the dilution factors of the plurality of dilution factors of the screening target fluid sample.
[0207] 55. The method of exemplary combination 54, wherein the plurality of screening blank control fluid samples comprises a blank fluid matrix of a screening sample fluid inventory, devoid of the target particles.
[0208] 56. A method according to any one of exemplary combinations 1-53, wherein the at least one screening blank control fluid sample comprises a screening buffer solution without the target particle, and optionally the screening control group contains only a single screening blank control fluid sample.
[0209] 57. The method of any one of exemplary combinations 1-56, wherein the target sample fluid inventory comprises the fluid matrix of the screening sample fluid inventory.
[0210] 58. The method of any one of exemplary combinations 1-57, wherein the screening sample fluid inventory is the same as the target sample fluid inventory.
[0211] 59. The method of any one of exemplary combinations 1-58, wherein the screening target set comprises a serial ten-fold dilution series of the screening sample fluid inventory.
[0212] 60. The method of any one of exemplary combinations 1-59, wherein the calculated concentration of the target particles in the target sample fluid inventory is based at least in part on an adjustment of the dilution factor of the optimized target set.
[0213] 61. The method of exemplary combination 60, wherein said executing said potency assay module comprises:
[0214] The dilution factor for the optimized target set is automatically retrieved to determine the particle titer result.
[0215] 62. A method according to any one of exemplary combinations 1-61, wherein said screening control set contains only a single said screening blank control fluid sample at each of said plurality of dilution factors.
[0216] 63. A method according to any one of exemplary combinations 1-62, wherein the optimization target group comprises a plurality of the optimized target fluid samples with a single optimized dilution factor within the optimized sample dilution factor range, optionally the plurality of optimized fluid samples comprises at least 3 of the optimized target fluid samples, preferably no more than 10 of the optimized target fluid samples, and more preferably 3 of the optimized target fluid samples.
[0217] 64. A method according to any one of exemplary combinations 1-63, wherein the optimized sample dilution factor range is bounded by an upper optimized dilution factor limit and a lower optimized dilution factor limit, neither of which is within the dilution factor of the multiple dilution factors of the screening target group.
[0218] 65. A method according to any one of exemplary combinations 1-64, wherein the target particle is a particle of biological material.
[0219] 66. A method according to any one of exemplary combinations 1-65, wherein the particle size of the target particles is less than 2 microns, preferably less than 1 micron, more preferably less than 600 nanometers, and even more preferably less than 300 nanometers.
[0220] 67. A method according to exemplary combination 66, wherein the particle size is at least 10 nanometers, preferably at least 20 nanometers, and even more preferably at least 30 nanometers.
[0221] 68. The method of any one of exemplary combinations 1-67, wherein:
[0222] Each of the screening target fluid sample, screening blank control fluid sample, optimization target fluid sample, and optimization blank control fluid sample is fluorescently colored to provide at least one fluorescent label on the target particle; and
[0223] Each of said flow cytometric assessments comprises detecting said responsive irradiation from said investigation region to detect a fluorescent emission response from said fluorescent label on said target particle.
[0224] 69. A method according to exemplary combination 68, wherein each of the flow cytometric evaluations includes detecting only the fluorescence emission response from the investigation area without detecting light scatter.
[0225] 70. A method according to exemplary combination 68 or exemplary combination 69, wherein the at least one fluorescent label comprises a non-specific nucleic acid label provided by a fluorescent dye.
[0226] 71. A method according to any one of exemplary combinations 68-70, wherein the at least one fluorescent label comprises a non-specific protein label provided by a second fluorescent dye.
[0227] 72. A method according to any one of exemplary combinations 68-71, wherein the at least one fluorescent label comprises an antibody staining that specifically binds to an epitope of the target particle.
[0228] 73. A method according to any one of exemplary combinations 68-71, wherein the target particle comprises a fluorescently labeled viral particle.
[0229] 74. A method according to any one of exemplary combinations 68-71, wherein the target particle comprises a fluorescently labeled virus-like particle.
[0230] 75. A method according to any one of exemplary combinations 68-71, wherein the target particles comprise fluorescently labeled exosomes.
[0231] 76. The method of any one of exemplary combinations 68-71, wherein the target particles comprise microbubbles.
[0232] 77. A method according to any one of exemplary combinations 68-76, wherein the at least one fluorescent marker comprises a plurality of fluorescent markers, and each of the flow cytometric assessments comprises detecting a separate fluorescent emission response from each of the plurality of fluorescent markers.
[0233] 78. A method according to exemplary combination 77, wherein each of the generating the flow cytometry results includes identifying consistent fluorescence emission responses from at least two of the fluorescent markers, indicating that the pathway through the investigation area of the target particle contains the at least two of the fluorescent markers.
[0234] 79. A method according to exemplary combination 78, wherein each of said generating said flow cytometry results includes counting each of said identified consistent fluorescence emission responses as a target particle.
[0235] 80. The method of any one of exemplary combinations 68-79, wherein the excitation radiation is provided from a single excitation radiation source.
[0236] 81. A method according to any one of exemplary combinations 68-80, wherein the excitation irradiation is provided from a plurality of different excitation irradiation sources, and the plurality of different excitation irradiation sources provide irradiation to the investigation area at different irradiation wavelength ranges.
[0237] 82. A method according to exemplary combination 80 or exemplary combination 81, wherein each of the excitation radiation sources is a light source and optionally includes a laser or a light emitting diode (LED).
[0238] 83. A method according to any one of exemplary combinations 1-82, wherein each of the flow cytometry assessments includes flowing the corresponding fluid sample through the investigation area at a flow rate in the range of from 600 nanoliters per minute to 3000 nanoliters per minute, and preferably from 600 nanoliters per minute to 2000 nanoliters per minute, while subjecting the corresponding fluid sample to the investigation excitation irradiation.
[0239] 84. A flow cytometric system for quantifying particles in a target sample fluid inventory, the flow cytometric system comprising:
[0240] a flow cytometer operable to flow a fluid sample through a flow cytometric investigation zone subjected to investigation excitation radiation, and to detect and measure response radiation from said investigation zone, and to determine and output a flow cytometric result comprising a quantitative indication of target particles having a particular particle attribute in each of said fluid samples;
[0241] a memory that receives and stores the flow cytometry results and includes the flow cytometry results for each of a screening target set of a plurality of screening target fluid samples, each of the screening target fluid samples comprising a screening sample fluid inventory for flow cytometric evaluation of the target particles, and the plurality of screening target fluid samples comprising a dilution series of the screening sample fluid inventory diluted at a plurality of dilution factors;
[0242] a graphical user interface comprising a display for presenting to a user a list of results corresponding to said flow cytometry results stored in said memory, and a user input device for receiving from a user a selection of said flow cytometry result from said list of results;
[0243] A screening assay module executable by a processor to configure the processor to:
[0244] accessing the memory to retrieve the flow cytometry results of the screening target group based on a first screening selection selected by the user from the results list,
[0245] calculating a corrected quantitative indication of the target particles for at least a plurality of portions of the screened target fluid sample of the first screened selection representing a plurality of dilution factors,
[0246] calculating a fit of the corrected quantitative indication relative to the plurality of dilution factors,
[0247] determining an optimized sample dilution factor range for flow cytometry studies of the screening sample fluid inventory using the flow cytometer instrument based on analysis of the fit of the corrected quantitative indications, and
[0248] presenting an indication of the optimized sample dilution factor range on a display of the graphical user interface;
[0249] wherein the memory is further operable to receive and store the flow cytometry results for each of an optimized target set of a plurality of optimized target fluid samples, the optimized target fluid samples each comprising a target sample fluid inventory of flow cytometric evaluations of the target particles having the specific particle attribute, wherein a plurality of optimized target fluid samples of the optimized target set comprise dilution factors of the target sample fluid inventory diluted to within the optimized sample dilution factor range; and
[0250] A potency assay module, executable by a processor to configure the processor to:
[0251] accessing the memory to retrieve the optimized target set of flow cytometry results based on a first titer selection selected by the user from the results list, and
[0252] Based on the flow cytometry results of the optimized target set of the first titer selection, particle titer results for the target sample fluid inventory are determined, and the particle titer results are presented on a display of the graphical user interface.
[0253] 85. A flow cytometry system according to exemplary combination 84, wherein the memory receives and stores the flow cytometry results of a screening control group having at least one screening blank control fluid sample corresponding to the screening target group.
[0254] 86. The flow cytometry system of exemplary combination 85, wherein the screening assay module is further operable to:
[0255] The flow cytometry results of the screening control set are retrieved based on a second screening selection selected by the user from the results list.
[0256] 87. The flow cytometry system of exemplary combination 86, wherein the screening assay module is further operable to:
[0257] Confirming that the second screening selection includes the flow cytometry results of the screening blank control fluid sample for each of a plurality of portions of the screening target fluid sample corresponding to the first screening selection.
[0258] 88. The flow cytometry system of exemplary combination 86 or exemplary combination 87, wherein the screening assay module is further operable to:
[0259] It is determined whether the quantitative indication of the target particles of each of the screened target fluid samples of the first screened selection is greater than the corresponding quantitative indication of the target particles of the screened control group of the second screened selection.
[0260] 89. A flow cytometry system according to exemplary combination 88, wherein multiple portions of the screening target fluid sample are confirmed as having the quantitative indication of the target particles that is greater than the corresponding quantitative indication of the target particles of the screening control group of the second screening selection.
[0261] 90. The flow cytometry system of any one of exemplary combinations 84-89, wherein the memory receives and stores the flow cytometry results of an optimized control group corresponding to the optimized target group having at least one optimized blank control fluid sample.
[0262] 91. The flow cytometry system of exemplary combination 90, wherein the titer assay module is further operable to:
[0263] The flow cytometry results of the optimized control set are retrieved based on a second titer selection selected by the user from the results list.
[0264] 92. A flow cytometry system according to exemplary combination 91, wherein the particle titer results of the target sample fluid inventory are the flow cytometry results based on the optimized target group selected by the first titer and the optimized control group selected by the second titer.
[0265] 93. The flow cytometry system of any one of exemplary combinations 84-92, wherein the screening assay module is further operable to:
[0266] The fitted one or more dilution quality parameters are compared to one or more acceptable dilution quality parameters.
[0267] 94. A flow cytometry system according to exemplary combination 93, wherein the optimized sample dilution factor range is based on multiple portions of the screening target fluid sample identified by the first screening selection having acceptable dilution quality parameters.
[0268] 95. A flow cytometric system for quantifying particles in a target sample fluid inventory, the flow cytometric system comprising:
[0269] a flow cytometer operable to flow a fluid sample through a flow cytometric investigation region subjected to investigation excitation radiation, and to detect and measure response radiation from said investigation region, and to determine and output a flow cytometric result comprising a quantitative indication of target particles having a particular particle attribute in said fluid sample;
[0270] a memory receiving and storing the flow cytometry results and comprising the flow cytometry results for each of a screening target group of a plurality of screening target fluid samples and the flow cytometry results for each of a screening control group having at least one screening blank control fluid sample corresponding to the screening target group, each of the screening target fluid samples comprising a screening sample fluid inventory for flow cytometric evaluation of the target particles, and the plurality of screening target fluid samples comprising a dilution series of the screening sample fluid inventory diluted at a plurality of dilution factors;
[0271] a graphical user interface comprising a display for presenting to a user a list of results corresponding to said flow cytometry results stored in said memory, and a user input device for receiving from a user a selection of said flow cytometry result from said list of results;
[0272] A screening assay module executable by a processor to configure the processor to:
[0273] accessing the memory to retrieve the flow cytometry results of the screening target group based on a first screening selection selected by the user from the result list, and accessing the memory to retrieve the flow cytometry results of the screening control group based on a second screening selection selected by the user from the result list,
[0274] confirming that the second screening selection includes the flow cytometry results of the screening blank control fluid sample corresponding to each of a plurality of screening target fluid samples of the first screening selection, and whether the quantitative indication of target particles of each of the screening target fluid samples of the first screening selection is greater than the corresponding quantitative indication of target particles of the screening control set of the second screening selection,
[0275] calculating a corrected quantitative indication of the target particle for at least a plurality of portions of the first screen selected screened target fluid sample representing a plurality of dilution factors identified as having the quantitative indication of the target particle greater than a corresponding quantitative indication of the target particle of the second screen selected screen control set,
[0276] calculating a fit of the corrected quantitative indication relative to the plurality of dilution factors,
[0277] comparing the fit relative to one or more acceptable dilution quality parameters,
[0278] determining an optimized sample dilution factor range for flow cytometric studies of the screening sample fluid inventory using the flow cytometer instrument based on the identified plurality of portions of the screening target fluid sample of the first screening selection having acceptable dilution quality parameters, and
[0279] presenting an indication of the optimized sample dilution factor range on a display of the graphical user interface;
[0280] wherein the memory is further operable to receive and store the flow cytometry results for each of an optimized target set of a plurality of optimized target fluid samples and the flow cytometry results for an optimized control set having at least one optimized blank control fluid sample corresponding to the optimized target set, the optimized target fluid samples each comprising a target sample fluid inventory for flow cytometry evaluation of the target particles having the specific particle attribute, wherein the plurality of optimized target fluid samples of the optimized target set comprise dilution factors of the titer sample fluid inventory diluted to within the optimized sample dilution factor range; and
[0281] A potency assay module, executable by a processor to configure the processor to:
[0282] accessing the memory to retrieve the flow cytometry results of the optimized target group based on a first valence selection selected by the user from the results list, and retrieving the flow cytometry results of the optimized control group based on a second valence selection selected by the user from the results list, and
[0283] Based on the flow cytometry results of the optimized target set for the first titer selection and the optimized control set for the second titer selection, particle titer results for the target sample fluid inventory are determined and presented on a display of the graphical user interface.
[0284] 96. The flow cytometry system of any one of exemplary combinations 84-95, wherein the titer assay module is further operable to:
[0285] calculating one or more potency parameters regarding the particle potency results, and
[0286] The one or more valence parameters are presented on a display of the graphical user interface.
[0287] 97. A flow cytometry system according to exemplary combination 96, wherein the one or more titer parameters include a standard deviation of the particle titer results.
[0288] 98. The flow cytometry system of exemplary combination 96 or exemplary combination 97, wherein the one or more titer parameters comprise a coefficient of variation of the particle titer results.
[0289] 99. The flow cytometry system of any one of exemplary combinations 96-98, wherein the titer assay module is further operable to:
[0290] If the one or more valence parameters are outside of corresponding acceptable valence parameters, an indication of a valence notification is provided.
[0291] 100. The flow cytometry system of any one of exemplary combinations 86 and 95-99, wherein the titer assay module is further operable to:
[0292] Determining a sample qualification restriction (SQL) for the flow cytometry results of the optimized target group selected by the first valency based on the flow cytometry results of the optimized control group selected by the second valency; and
[0293] If the flow cytometry results for any one of the optimization target groups do not exceed the SQL, an indication of an SQL notification is provided.
[0294] 101. The flow cytometry system of any one of exemplary combinations 94-100, wherein the screening assay module is further operable to:
[0295] If the fitting of the plurality of portions of the screened target fluid sample of the first screened selection does not provide the fit having a dilution quality parameter that meets the acceptable dilution quality parameter, an indication of a fit notification is provided.
[0296] 102. A flow cytometry system according to exemplary combination 101, wherein the fitting comprises a linear regression fit calculated relative to the group-corrected quantitative indication and a logarithmic transformation of the plurality of dilution factors.
[0297] 103. A flow cytometry system according to exemplary combination 102, wherein the one or more dilution quality parameters include a quantitative characterization of the linear regression fit.
[0298] 104. A flow cytometry system according to exemplary combination 102 or exemplary combination 103, wherein the linear regression fit is represented as a trend line of the logarithmic transformation relative to the corrected quantitative indication and the multiple dilution factors, and wherein the dilution quality parameter includes the slope and coefficient of determination of the trend line.
[0299] 105. A flow cytometry system according to exemplary combination 104, wherein the logarithmic transformation of the group-corrected quantitative indication is displayed in a curve on the display of the graphical user interface relative to the corresponding multiple dilution factors, and wherein the trend line is displayed in the curve relative to the corrected quantitative indication.
[0300] 106. The flow cytometry system of exemplary combination 105, wherein an idealized trend line is displayed in the curve.
[0301] 107. The flow cytometry system of exemplary combination 105 or exemplary combination 106, wherein the screening assay module is further operable to:
[0302] If the screening of the plurality of portions of the target fluid sample does not generate a graphable result, a graphical notification indication is provided.
[0303] 108. A flow cytometry system according to any one of exemplary combinations 104-107, wherein the acceptable quality parameters include an acceptable slope value of the trend line and an acceptable coefficient of determination of the trend line.
[0304] 109. A flow cytometry system according to exemplary combination 108, wherein the acceptable slope value comprises a range of acceptable slope values, and the acceptable coefficient of determination comprises a range of acceptable fit coefficients of determination.
[0305] 110. A flow cytometry system according to exemplary combination 109, wherein the optimized sample dilution factor range is within the multiple dilution factors of the multiple portions of the screening target fluid sample selected by the first screening, wherein the slope value is within the acceptable slope value, and the determination coefficient is within the range of acceptable fitting determination coefficients.
[0306] 111. A flow cytometry system according to any one of exemplary combinations 104-110, wherein the optimized sample dilution factor range is defined between an upper optimized dilution factor limit and a lower optimized dilution factor limit, wherein the upper optimized dilution factor limit corresponds to the dilution value of the trend line corresponding to the lower performance concentration limit, and the lower optimized dilution factor limit corresponds to the dilution value of the trend line corresponding to the upper performance concentration limit.
[0307] 112. A flow cytometry system according to any one of exemplary combinations 94-111, wherein the screening assay module is further operable to present a verification prompt on a display of the graphical user interface, prompting the user to confirm the dilution quality parameters of the fit.
[0308] 113. A flow cytometry system according to any one of exemplary combinations 94-112, wherein determining the optimized sample dilution factor range includes removing from a first plurality of portions of the screening target fluid sample selected from the first screening the flow cytometry results corresponding to either or both of a maximum dilution factor or a minimum dilution factor that do not provide the corresponding acceptable quality dilution parameters of the fit for the first plurality of portions.
[0309] 114. A flow cytometry system according to exemplary combination 113, wherein the graphical user interface includes an input for removing the flow cytometry result corresponding to the maximum dilution factor or the minimum dilution factor.
[0310] 115. The flow cytometry system of any one of exemplary combination 89 and exemplary combinations 95-114, wherein the screening assay module is further operable to:
[0311] If the quantification of particles of the target fluid sample of the first screening selection is not greater than the corresponding quantification of particles of the screen control set of the second screening selection, an indication of a corrected quantification indication notification is provided.
[0312] 116. The flow cytometry system of any one of exemplary combinations 84-115, wherein the screening assay module is further operable to:
[0313] If the optimized sample dilution factor range is outside of the absolute acceptable dilution factors for the flow cytometer, an indication of a dilution factor notification is provided.
[0314] 117. A flow cytometry system according to any one of exemplary combinations 84-116, wherein the indication of the optimized sample dilution factor range includes highlighting the upper and lower limits of the optimized sample dilution factor range on the display of the graphical user interface.
[0315] 118. A flow cytometry system according to any one of exemplary combinations 84-117, wherein the indication of the optimized sample dilution factor range includes at least one optimized dilution value, and the at least one optimized dilution value includes a rounded dilution value within the optimized sample dilution factor range.
[0316] 119. A flow cytometry system according to any one of exemplary combinations 84-118, wherein the screening assay module is further operable to generate dilution instructions to prepare the optimized target group of the multiple optimized target fluid samples within the optimized sample dilution factor range, and present the dilution instructions to the user on the display of the graphical user interface.
[0317] 120. A flow cytometry system according to any one of exemplary combinations 84-119, wherein the titer assay module is further operable to confirm that the flow cytometry results of the plurality of samples selected for the first titer include an acceptable dilution factor.
[0318] 121. The flow cytometry system of exemplary combination 120, wherein the acceptable dilution factor is within the range of the optimized sample dilution factor.
[0319] 122. The flow cytometry system of any one of exemplary combinations 84-121, wherein the titer assay module is further operable to:
[0320] When any of the flow cytometry results for the plurality of samples for the first titer selection does not include the acceptable dilution factor, an indication of a titer dilution notification is provided on a display of the graphical user interface.
[0321] 123. A flow cytometry system according to any one of exemplary combinations 94-122, wherein the acceptable quality parameters are definable by the user.
[0322] 124. A flow cytometry system according to exemplary combination 123, wherein the graphical user interface includes an acceptable quality parameter input for use in defining the acceptable quality parameters by the user.
[0323] 125. A flow cytometry system according to any one of exemplary combinations 84 and 95-124, wherein the screening control group includes a plurality of screening blank control fluid samples, and the plurality of screening blank control fluid samples correspond to the plurality of dilution factors of the screening target fluid samples.
[0324] 126. A flow cytometry system according to exemplary combination 125, wherein the plurality of screening blank control fluid samples include a blank matrix that does not contain the target particles having specific particle properties of the screening sample fluid inventory.
[0325] 127. A flow cytometry system according to any one of exemplary combinations 84 and 95-124, wherein the dilution series of the multiple screening target fluid samples are diluted with a screening buffer solution, and wherein at least one screening blank control fluid sample includes the screening buffer solution, which does not contain the target particles having specific particle properties of the screening sample fluid inventory.
[0326] 128. A flow cytometry system according to any of exemplary combinations 84-127, wherein the target sample fluid inventory includes the screening sample fluid inventory.
[0327] 129. A flow cytometry system according to any of exemplary combinations 84-127, wherein the screening sample fluid inventory is an equivalent approximation of the target sample fluid inventory.
[0328] 130. A flow cytometry system according to any one of exemplary combinations 84-127, wherein the target sample screening set comprises a serial ten-fold dilution series of the screening sample fluid stock.
[0329] 131. A flow cytometry system according to any one of exemplary combinations 84-130, wherein the particle titer result is based at least in part on the dilution factor of the optimized target group.
[0330] 132. A flow cytometry system according to any one of exemplary combinations 84-131, wherein the titer assay module is operable to automatically retrieve the dilution factor of the optimized target group to determine a particle titer result.
[0331] 133. A flow cytometry system according to any one of exemplary combinations 84-132, wherein the particle titer result comprises a calculated concentration of the target particles in the target sample fluid inventory.
[0332] 134. A flow cytometry system according to any one of exemplary combinations 84-133, wherein the target particles are particles of biological material.
[0333] 135. A flow cytometry system according to any one of exemplary combinations 1-134, wherein the particle size of the target particles is less than 2 microns, preferably less than 1 micron, more preferably less than 600 nanometers, and even more preferably less than 300 nanometers.
[0334] 136. A flow cytometry system according to exemplary combination 135, wherein the particle size is at least 10 nanometers, preferably at least 20 nanometers, and even more preferably at least 30 nanometers.
[0335] 137. The flow cytometry system of any one of exemplary combinations 84-136, wherein:
[0336] Each of the screening target fluid sample, screening blank control fluid sample, optimization target fluid sample, and optimization blank control fluid sample is fluorescently colored to provide at least one fluorescent label on the target particle; and
[0337] The flow cytometer is operable to detect the responsive irradiation from the investigation region to detect a fluorescent emission response from the fluorescent label on the target particle.
[0338] 138. A flow cytometer system according to exemplary combination 137, wherein the flow cytometer is operable to detect only fluorescence emission responses from the investigation area without detecting light scattering.
[0339] 139. A flow cytometry system according to exemplary combination 137 or 138, wherein at least one of the fluorescent markers comprises a non-specific nucleic acid marker provided by a fluorescent dye.
[0340] 140. A flow cytometry system according to any one of exemplary combinations 137-139, wherein the at least one fluorescent marker comprises a non-specific protein marker provided by a second fluorescent dye.
[0341] 141. A flow cytometry system according to any one of exemplary combinations 137-140, wherein the at least one fluorescent marker comprises an antibody staining that specifically binds to an epitope of the target particle.
[0342] 142. A flow cytometry system according to any one of exemplary combinations 137-140, wherein the target particles comprise fluorescently labeled viral particles.
[0343] 143. A flow cytometry system according to any one of exemplary combinations 137-141, wherein the target particles comprise fluorescently labeled virus-like particles.
[0344] 144. A flow cytometry system according to any one of exemplary combinations 137-141, wherein the target particles comprise fluorescently labeled exosomes.
[0345] 145. A flow cytometry system according to any one of exemplary combinations 137-141, wherein the target particles comprise microbubbles.
[0346] 146. A flow cytometer system according to any one of exemplary combinations 137-145, wherein the at least one fluorescent marker comprises a plurality of fluorescent markers, and the flow cytometer is operable to detect a separate fluorescent emission response from each of the plurality of fluorescent markers.
[0347] 147. A flow cytometer system according to exemplary combination 146, wherein the flow cytometer is operable to identify consistent fluorescence emission responses from at least two of the fluorescent markers, indicating that the path through the investigation area of the target particle contains the at least two of the fluorescent markers, and determine a particle titer result based at least in part on the identified consistent fluorescence emission responses.
[0348] 148. A flow cytometer system according to exemplary combination 147, wherein the flow cytometer is operable to count occurrences of the identified consistent fluorescence emission responses as target particles.
[0349] 149. A flow cytometer system according to any one of exemplary combinations 137-148, wherein the excitation radiation is provided from a single excitation radiation source of the flow cytometer.
[0350] 150. A flow cytometer system according to any one of exemplary combinations 137-148, wherein the excitation irradiation is provided from multiple different excitation irradiation sources of the flow cytometer, and each of the multiple different excitation irradiation sources provides irradiation to the investigation area at a different range of irradiation wavelengths.
[0351] 151. A flow cytometry system according to exemplary combination 149 or 150, wherein each of the excitation radiation sources is a light source and optionally includes a laser or a light emitting diode (LED).
[0352] 152. A flow cytometer system according to any one of exemplary combinations 84-151, wherein the flow cytometer is operable to cause the corresponding fluid sample to flow through the investigation area at a controlled flow rate, wherein the controlled flow rate ranges from 600 nanoliters per minute to 3000 nanoliters per minute, and preferably from 600 nanoliters per minute to 2000 nanoliters per minute, while subjecting the corresponding fluid sample to the investigation excitation irradiation.
[0353] 153. The flow cytometry system of any one of exemplary combinations 84-151, configured to perform the method of any one of exemplary combinations 1-83 or any feature of the method.
[0354] 154. Use of the flow cytometry system of any one of exemplary combinations 84-151 for performing the method of any one of exemplary combinations 1-83.
[0355] 155. Use of a flow cytometry system according to any one of exemplary combinations 84-151 to determine a titer result of target particles in a target sample fluid inventory, optionally including a calculated concentration of the target in the target sample fluid inventory.
[0356] The description of one or more features in a particular combination does not exclude the inclusion of one or more additional features in variations of the particular combination. The processing steps and order are for illustration only, and such description does not exclude other steps or other order of steps, to the extent that they are not necessarily incompatible. Additional steps may be included between any illustrated processing steps or before or after any illustrated processing steps, to the extent that they are not necessarily incompatible.
[0357] The terms "includes," "comprising," "including," and "having," and grammatical variations of these terms are intended to be inclusive and non-limiting, in that the use of such terms indicates the presence of the stated condition or feature, but does not exclude the presence of any other condition or feature. The use of the terms "includes," "comprising," "including," and "having," and grammatical variations of these terms (referring to the presence of one or more components, subcomponents, or materials) also include and are intended to disclose more specific embodiments, wherein the terms "includes," "comprising," "including," or "having" (or variations of such terms), as appropriate, may be replaced by the narrower terms "consisting essentially of," "consisting of," or "consisting only of" (or any appropriate grammatical variations of such narrow terms). For example, a statement that something "includes" one or more of the stated elements is also intended to include and disclose more specific narrower embodiments of the thing "consisting essentially of" the stated one or more elements and the thing "consisting of" the stated one or more elements. Examples of various features have been provided for purposes of illustration, and the terms "example," "for example," and the like indicate illustrative examples, which are not limiting, and should not be construed or interpreted as limiting one or more features to the features of any particular example. The term "at least" followed by a number (e.g., "at least one") means that number or greater than that number. As used herein, a range of a feature refers to one or more values of that feature within an upper and lower limit (including the upper and lower limits), and includes the case where the upper and lower limits are the same, that is, when the range contains a single value represented by an equal upper and lower limit.
Claims
1. A flow cytometric method for quantifying target particles having specific particle attributes in a target sample fluid inventory using a flow cytometer, the flow cytometer being operable to flow the fluid sample through a flow cytometric investigation zone subjected to investigation excitation radiation, and to detect and measure response radiation from the investigation zone, and to determine and output a flow cytometric result, the flow cytometric result comprising a quantitative indication of the target particles in each of the fluid samples, the method comprising: subjecting a screening target set of screening target fluid samples comprising a dilution series of a screening sample fluid stock diluted at a plurality of dilution factors to a first flow cytometry evaluation, wherein the subjecting to the first flow cytometry evaluation comprises: causing each of the screening target fluid samples to flow through an investigation zone of the flow cytometer and subjecting each of the screening target fluid samples to the investigation excitation radiation in the investigation zone, detecting the responsive radiation from the investigation zone and generating a flow cytometry result for each of the screened target fluid samples, the flow cytometry result comprising the quantitative indication of the target particles of the screened target fluid sample, and storing the flow cytometry results of the screening target group in a computer memory, the memory having stored therein a screening assay module and a titer assay module, the screening assay module being accessible and executable by a processor, and the titer assay module being accessible and executable by the processor; executing the screening assay module by the processor, wherein the executing the screening assay module comprises: calculating a corrected quantitative indication for each of at least a plurality of portions of the screening target fluid sample, comprising comparing a first selected flow cytometry result of the screening target set from the memory to a corresponding second selected flow cytometry result of a screening control set selected from the memory, the screening control set comprising at least one screening blank control fluid sample corresponding to the screening target set, and adjusting the quantitative indication of the first selected flow cytometry result to the corrected quantitative indication based at least in part on the comparison, and determining an optimized sample dilution factor range for the screening sample fluid inventory based on analysis of the corrected quantitative indication, and storing the optimized sample dilution factor range in the memory; subjecting an optimized target set of optimized target fluid samples, each of which comprises the target sample fluid stock diluted to an optimized sample dilution factor within the range of optimized sample dilution factors, to a second flow cytometry evaluation, wherein the subjecting to a second flow cytometry evaluation comprises: flowing each of the optimized target fluid samples through an investigation zone of the flow cytometer and subjecting each of the optimized target fluid samples to the investigation excitation radiation in the investigation zone, detecting the responsive radiation from the investigation region and generating the flow cytometry result for each of the optimized target fluid samples, the flow cytometry result comprising the quantitative indication of the target particles of the optimized target fluid sample, and storing the flow cytometry results of the optimized target group in the memory; Executing the potency assay module with the processor, wherein executing the potency assay module comprises: accessing the optimized target set of flow cytometry results in the memory, and Using the flow cytometry results of the optimized target set, calculating particle titer results for the target sample fluid inventory; and Particle titer results for the target sample fluid inventory are stored in the memory.
2. The method according to claim 1, further comprising: displaying a list of results corresponding to the flow cytometry results stored in the memory on a display of a graphical user interface having a user input device; as well as A first titer selection is received from the user by a user input device of the graphical user interface, the first titer selection comprising a flow cytometry result of the optimized target fluid sample selected by the user from the list of results.
3. The method according to claim 1, further comprising: subjecting the screening control set including the at least one screening blank control fluid sample to a third flow cytometry evaluation, the subjecting the screening control set including the at least one screening blank control fluid sample to a third flow cytometry evaluation comprising: flowing each of the screening blank control fluid samples through the flow cytometer investigation zone and subjecting each of the screening blank control fluid samples to the investigation excitation radiation in the investigation zone, detecting the response radiation from the investigation area and generating the flow cytometry result for each of the screening blank control fluid samples, the flow cytometry result comprising the quantitative indication of the target particles of the screening blank control fluid sample; receiving, by a user input device of the graphical user interface, a second screening selection from a user, the second screening selection comprising flow cytometry results for the at least one screening blank control fluid sample from a list of results displayed on the graphical user interface; and Based on the second screening selection selected by the user from the results list, the memory is accessed to retrieve a second selected flow cytometry result of the at least one screening blank control fluid sample.
4. The method according to claim 1, wherein the step of executing the titer assay module further comprises: The particle titer results of the target sample fluid inventory are calculated using the flow cytometry results of the optimized target set and an optimized control set, the optimized control set including at least one optimized blank control fluid sample corresponding to the optimized target set.
5. The method according to claim 4, wherein the performing the titer assay module further comprises: Based on the flow cytometry results of the optimized control group, determining the sample qualification restriction SQL of the flow cytometry results of the optimized target group; as well as If the flow cytometry results of any one of the optimization target groups do not exceed the SQL, an indication of SQL notification is provided on the graphical user interface.
6. The method according to claim 4, further comprising: subjecting the optimized control set including the at least one optimized blank control fluid sample to a fourth flow cytometry evaluation, the subjecting the optimized control set including the at least one optimized blank control fluid sample to a fourth flow cytometry evaluation comprising: flowing each of the optimized blank control fluid samples through the investigation zone and subjecting each of the optimized blank control fluid samples to the investigation excitation radiation in the investigation zone, and The responsive radiation from the investigation region is detected, and the flow cytometry result is generated for each of the optimized blank control fluid samples, the flow cytometry result comprising the quantitative indication of the target particles of the optimized blank control fluid sample.
7. The method of claim 1, wherein said performing said screening assay module further comprises: first determining whether a first condition exists in which the flow cytometry result of the screening blank control fluid sample exists, the screening blank control fluid sample corresponding to each of the screening target fluid samples of a plurality of portions of the screening target fluid samples; as well as When it is determined during the first determination that such a first condition does not exist, a corresponding notification is provided.
8. The method of claim 1, wherein determining an optimal sample dilution factor in said performing said screening assay module further comprises: A fit of the corrected quantitative indication is calculated relative to a plurality of the dilution factors of the dilution series, wherein a plurality of portions of the screening target fluid sample of the first selected flow cytometry result represent the plurality of the dilution factors.
9. The method of claim 8, wherein said performing said screening assay module further comprises: comparing the fit relative to one or more dilution quality parameters, wherein the optimized sample dilution factor range is determined after the fit meets an acceptable dilution quality parameter; as well as If the fit of the plurality of portions of the screened target fluid sample does not meet the acceptable dilution quality parameter, an indication of a fit notification is provided.
10. The method of claim 9, wherein said calculating said fit comprises determining a linear regression fit relative to a logarithmic transformation of said corrected quantitative indication and said plurality of dilution factors; and The one or more dilution quality parameters include a quantitative characterization of the linear regression fit.
11. The method according to any one of claims 8 to 10, wherein the calculating the fit further comprises: At least one of the screening target fluid samples having a maximum of the dilution factor or a minimum of the dilution factor among the plurality of dilution factors is removed from determining the fit, wherein the fit is determined excluding any of the corrected quantitative indications for each removed screening target fluid sample.
12. The method according to any one of claims 8 to 10, wherein The optimized sample dilution factor range is defined between an upper optimized dilution factor limit and a lower optimized dilution factor limit, wherein the upper optimized dilution factor limit corresponds to the dilution value on the fit corresponding to the lower optimized performance concentration limit, and the lower optimized dilution factor limit corresponds to the dilution value on the fit corresponding to the upper optimized performance concentration limit.
13. The method of claim 12, wherein the lower optimal performance concentration limit is at least 10 6.5 Particles; The upper optimization performance concentration limit is no more than 10 per milliliter 8 Particles; The lower optimal performance concentration limit and the upper optimal performance concentration limit define an optimal performance subrange within a dynamic range of the flow cytometer determined by particle concentration; and The upper optimization performance concentration limit is no greater than 10 times the lower optimization performance concentration limit.
14. The method of claim 12, wherein said performing said screening assay module further comprises: An indication of the optimized sample dilution factor range is provided to the user.
15. The method according to any one of claims 1 to 10, wherein: The particle titer result includes a calculated concentration of the target particle in the target sample fluid inventory; The performing the potency assay module further comprises calculating one or more potency parameters related to the particle potency result; The one or more potency parameters include a standard deviation corresponding to a plurality of the concentrations of a plurality of the optimized target fluid samples; The one or more potency parameters include coefficients corresponding to variations in a plurality of the concentrations of a plurality of the optimized target fluid samples; and If it is determined that the potency parameter is outside of a corresponding acceptable potency parameter value range, the performing the potency assay module further includes providing an indication of a potency notification on a graphical user interface.
16. The method according to any one of claims 1-10, wherein the screening control set includes a plurality of the screening blank control fluid samples, wherein at least one of the screening blank control fluid samples corresponds to each of the dilution factors of a plurality of dilution factors of the screening target fluid sample.
17. A flow cytometric system for quantifying particles in a target sample fluid inventory, the flow cytometric system comprising: a flow cytometer operable to flow a fluid sample through a flow cytometric investigation zone subjected to investigation excitation radiation, and to detect and measure response radiation from said investigation zone, and to determine and output a flow cytometric result comprising a quantitative indication of target particles having a particular particle attribute in each of said fluid samples; a memory that receives and stores the flow cytometry results and includes the flow cytometry results for each of a screening target set of a plurality of screening target fluid samples, each of the screening target fluid samples comprising a screening sample fluid inventory for flow cytometric evaluation of the target particles, and the plurality of screening target fluid samples comprising a dilution series of the screening sample fluid inventory diluted at a plurality of dilution factors; a graphical user interface comprising a display and a user input device, the display being for presenting to a user a list of results corresponding to the flow cytometry results stored in the memory, the user input device being for receiving from a user a selection of the flow cytometry result from the list of results; A screening assay module executable by a processor to configure the processor to: accessing the memory to retrieve the flow cytometry results of the screening target group based on a first screening selection selected by the user from the results list, calculating a corrected quantitative indication of said target particles for at least a plurality of portions of said first screen selected screening target fluid sample representing a plurality of said dilution factors of said dilution series, calculating a fit of said corrected quantitative indication relative to said plurality of said dilution factors, determining an optimized sample dilution factor range for flow cytometry studies of the screening sample fluid inventory using the flow cytometer based on analysis of the fit of the corrected quantitative indications, and presenting an indication of the optimized sample dilution factor range on a display of the graphical user interface; wherein the memory is further operable to receive and store the flow cytometry results for each of an optimized target set of a plurality of optimized target fluid samples, the optimized target fluid samples each comprising a target sample fluid inventory of a flow cytometric evaluation of the target particles having the specific particle attribute, wherein a plurality of optimized target fluid samples of the optimized target set comprise dilution factors of the target sample fluid inventory diluted to within the optimized sample dilution factor range; as well as A potency assay module, executable by the processor to configure the processor to: accessing the memory to retrieve the optimized target set of flow cytometry results based on a first titer selection selected by the user from the results list, and Based on the flow cytometry results of the optimized target group selected by the first titer, A particle titer result for the target sample fluid inventory is determined and the particle titer result is presented on a display of the graphical user interface.
18. A flow cytometric system for quantifying particles in a target sample fluid inventory, the flow cytometric system comprising: a flow cytometer operable to flow a fluid sample through a flow cytometric investigation zone subjected to investigation excitation radiation, and to detect and measure response radiation from said investigation zone, and to determine and output a flow cytometric result comprising a quantitative indication of target particles having a particular particle attribute in each of said fluid samples; a memory receiving and storing the flow cytometry results and comprising the flow cytometry results for each of a screening target group of a plurality of screening target fluid samples and the flow cytometry results for each of a screening control group having at least one screening blank control fluid sample corresponding to the screening target group, each of the screening target fluid samples comprising a screening sample fluid inventory for flow cytometric evaluation of the target particles, and the plurality of screening target fluid samples comprising a dilution series of the screening sample fluid inventory diluted at a plurality of dilution factors; a graphical user interface comprising a display and a user input device, the display being for presenting to a user a list of results corresponding to the flow cytometry results stored in the memory, the user input device being for receiving from a user a selection of the flow cytometry result from the list of results; A screening assay module executable by a processor to configure the processor to: accessing the memory to retrieve the flow cytometry results of the screening target group based on a first screening selection selected by the user from the result list, and accessing the memory to retrieve the flow cytometry results of the screening control group based on a second screening selection selected by the user from the result list, confirming that the second screening selection includes the flow cytometry results of the screening blank control fluid sample corresponding to each of a plurality of screening target fluid samples of the first screening selection, and whether the quantitative indication of target particles of each of the screening target fluid samples of the first screening selection is greater than the corresponding quantitative indication of target particles of the screening control set of the second screening selection, calculating a corrected quantitative indication of said target particles for at least a plurality of portions of said first screen selected screened target fluid sample representing a plurality of dilution factors identified as having said quantitative indication of said target particles greater than corresponding said quantitative indications of target particles of a screen control set of said second screen selected, calculating a fit of the corrected quantitative indication relative to the plurality of dilution factors, comparing the fit relative to one or more acceptable dilution quality parameters, determining an optimized sample dilution factor range for a flow cytometric study of the screening sample fluid inventory using the flow cytometer based on the identified plurality of portions of the screening target fluid sample of the first screening selection having the one or more acceptable dilution quality parameters, and presenting an indication of the optimized sample dilution factor range on a display of the graphical user interface; wherein the memory is further operable to receive and store the flow cytometry results for each of an optimized target set of a plurality of optimized target fluid samples and the flow cytometry results for an optimized control set having at least one optimized blank control fluid sample corresponding to the optimized target set, the optimized target fluid samples each comprising a target sample fluid inventory of a flow cytometric evaluation of the target particles having the specific particle attribute, wherein the plurality of optimized target fluid samples of the optimized target set comprise a dilution factor of the target sample fluid inventory diluted to within the range of the optimized sample dilution factors; as well as A potency assay module, executable by the processor to configure the processor to: accessing the memory to retrieve the flow cytometry results of the optimized target group based on a first titer selection selected by the user from the result list, and to retrieve the flow cytometry results of the optimized control group based on a second titer selection selected by the user from the result list, and Based on the flow cytometry results of the optimized target set for the first titer selection and the optimized control set for the second titer selection, a particle titer result for the target sample fluid inventory is determined and presented on a display of the graphical user interface.
19. The flow cytometry system according to claim 18, wherein the titer assay module is further operable to: calculating one or more potency parameters regarding the particle potency results, presenting the one or more valence parameters on a display of the graphical user interface; and If the one or more valence parameters are outside of corresponding acceptable valence parameters, an indication of a valence notification is provided.
20. The flow cytometry system of claim 18, wherein the titer assay module is further operable to: Determining the sample qualification restriction SQL of the flow cytometry results of the optimized target group selected by the first valence based on the flow cytometry results of the optimized control group selected by the second valence; and If the flow cytometry results of any one of the optimization target groups do not exceed the SQL, an indication of SQL notification is provided.
21. The flow cytometry system of any one of claims 18-20, wherein the screening assay module is further operable to: If the fitting of the plurality of portions of the screened target fluid sample of the first screened selection does not provide the fit having a dilution quality parameter that complies with the one or more acceptable dilution quality parameters, an indication of a fit notification is provided.
22. The flow cytometry system of claim 21, wherein: The fitting comprises a linear regression fit calculated relative to a logarithmic transformation of the set of corrected quantitative indicators and the plurality of dilution factors; The one or more dilution quality parameters include a quantitative characterization of the linear regression fit; The linear regression fit is represented as a log-transformed trend line relative to the corrected quantitative indication and the plurality of dilution factors, and wherein the dilution quality parameter comprises a slope and a coefficient of determination of the trend line; and The optimized sample dilution factor range is defined between an upper optimized dilution factor limit and a lower optimized dilution factor limit, wherein the upper optimized dilution factor limit corresponds to the dilution value of the trend line corresponding to the lower performance concentration limit, and the lower optimized dilution factor limit corresponds to the dilution value of the trend line corresponding to the upper performance concentration limit.
23. The flow cytometry system according to any one of claims 18 to 20, wherein the titer assay module is further operable to: confirming that the flow cytometry results of the first titer selected optimized target fluid sample include an acceptable dilution factor within the optimized sample dilution factor range; and When any of the flow cytometry results of the first titer selected optimized target fluid sample does not include the acceptable dilution factor, an indication of a titer dilution notification is provided on the display of the graphical user interface.
Citation Information
Patent Citations
Flow measurement and control for improved quantification of particles in flow cytometry
US10031061B2
Evaluating biological material for unassociated virus-size particles with influenza virus epitope
US10161850B2
Flow cytometry with data analysis for optimized dilution of fluid samples for flow cytometry investigation
US20200232900A1
Processing biological material for flow cytometry evaluation for virus particles
US9546936B2
Flow cytometer signal peak identification employing dynamic thresholding
US9903803B2
